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ABSTRACT
Purpose: To compare baseline CVD risk factor profiles among groups of individuals with 
discordant levels of  high- and low-density lipoprotein cholesterol  (HDL-C and LDL-C 
respectively) compared to lipoprotein particle concentration  (HDL-P  and LDL-P 
respectively) and examine the associations between lipoprotein discordance and incident 
type 2 diabetes mellitus (T2D) and metabolic syndrome (MetS). Furthermore, to examine 
the association between lipoprotein discordance and exercise induced changes in CVD risk 
factors. 
Methods: Standard lipid panels as well as lipoprotein subclass profiles via nuclear 
magnetic resonance spectroscopy were measured among three previously completed 
studies (CARDIA cohort, HERITAGE Family Study, and HART-D study) spanning over 
4,000 male and female participants. 1) Aerobic training only (AT), 2) Resistance training 
only (RT), 3) Combined AT/RT. Four exclusive HDL and LDL discordance groups were 
created based on baseline median lipoprotein cholesterol/particle concentrations as 
follows: 1) low/low (< median for both cholesterol and particle), 2) low/high (< median 
cholesterol, ≥ median particle), 3) high/low, and 4) high/high. Cross-sectional associations 
between baseline discordance group and CVD risk factors were assessed via multivariable 
linear regression. Continuous discordance levels were created by subtracting individual 
particle percentile ranking from cholesterol percentile ranking (e.g. HDL-C – HDL-P).  The 
association between continuous lipoprotein discordance and cross-sectional CVD risk 
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factors was assessed correlational analysis, while the association of incident T2D or MetS 
with lipoprotein discordance was assessed via multivariable proportional hazards 
regression. The relationship between lipoprotein discordance and exercise induced changes 
in CVD risk factors was assessed via multivariable linear regression.  
Results: Cross sectional analyses revealed that for HDL discordance, more favorable risk 
profiles (e.g. lower BMI, larger mean HDL-P and LDL-P size) were associated with higher 
HDL-C, while in LDL discordance groups more favorable risk factors were associated with 
lower LDL-P. In women only, both HDL and LDL discordance were associated with T2D 
and MetS risk with higher risk being associated with lower HDL-C and higher LDL-P. 
Associations of lipoprotein discordance with exercise induced changes in CVD risk factors 
were primarily limited to lipoprotein specific variables (e.g. HDL discordance significantly 
associated with changes in mean HDL-P size). 
Conclusions: Lipoprotein discordance is associated with cross-sectional differences in 
CVD risk factors with more favorable risk factor profiles being found in those with high 
HDL-C and low LDL-P regardless of discordance status. Lipoprotein 
concordant/discordant status is also a significant risk factor for both T2D and MetS in 
women only, although racial disparities may be present. Furthermore, lipoprotein 
discordance status is primarily associated with exercise training induced changes in 
lipoprotein subclass measures. Thus, while lipoprotein discordance is minimally predictive 
of exercise training responses outside of lipoprotein subclass measures, our findings 
support the regular measurement of lipoprotein particle concentrations alongside of 
cholesterol measures in chronic disease management and prevention. 
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CHAPTER 1 
INTRODUCTION 
 
Cholesterol levels of both low-density (LDL-C) and high-density (HDL-C) 
lipoproteins have been regularly associated with cardiovascular disease (CVD) risk. A 
large body of evidence supports a positive association between LDL-C and CVD 1-3, while 
HDL-C levels display an inverse relationship with CVD.3-6 Collective data from 26 
randomized trials supports intensive LDL-C lowering as a means to reducing CVD risk.7 
Many patients with well controlled LDL-C, however, still have considerable residual CVD 
risk, with an average of nine percent of treated patients from prospective studies of optimal 
statin therapy still experiencing major CVD events.8  Low HDL-C levels are largely 
supported in epidemiological literature as a risk factor for CVD, however, randomized 
controlled trials with niacin or inhibitors of cholesterol ester transfer protein have not 
improved CVD outcomes despite significant increases in HDL-C levels.9-12 Thus, 
cholesterol content may not fully capture the risk associated with these lipoprotein 
particles. 
Both LDL and HDL are largely heterogeneous lipoproteins, varying in size, 
density, composition and function. Advanced techniques such as nuclear magnetic 
resonance (NMR) and vertical auto profile are able to provide subclass measurements of 
these lipoproteins, revealing their diversity and offering alternative measures to cholesterol 
content in estimating CVD risk. One popular alternative to cholesterol content is measuring
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the concentration of both LDL and HDL particles (LDL-P and HDL-P respectively). While 
both LDL-C and HDL-C measure the amount of cholesterol bound to these particles, LDL-
P and HDL-P represent the number of respective particles carrying this cholesterol load. 
When comparing LDL-P to LDL-C, total LDL-P has been shown to have stronger 
associations with both subclinical disease13 and CVD events14, 15 than LDL-C, with 
increased LDL-P levels associated with higher risk. Similarly, analysis from the Multi-
Ethnic Study of Atherosclerosis (MESA) found total HDL-P to have an independent, 
inverse association with coronary heart disease (CHD) and subclinical disease, while HDL-
C was not significantly associated when both HDL-P and HDL-C were included in the 
model.16 Conventional analyses like these use both cholesterol content and particle 
concentration separately in statistical models to predict risk, thus treating them as 
independent predictors. However, both LDL-C and HDL-C are not biologically 
independent of their particle concentrations and treating them as such may not account for 
the biological similarities represented by each variable.  
One way to account for both the biological similarities and differences represented 
by cholesterol content and particle concentration is lipoprotein discordance analysis. 
Lipoprotein discordance analyses have traditionally used standardized lipoprotein 
cholesterol concentrations and made ratios of these numbers with standardized lipoprotein 
particle concentration or a non-cholesterol variant (e.g., LDL-C/LDL-P). From this ratio, 
a level of concordance/discordance can be derived, representing the relative similarity 
between an individual’s cholesterol and particle concentration measures. This similarity is 
gauged by ranking an individual’s cholesterol and particle concentrations amongst their 
respective study population. Individuals are deemed concordant if their rankings for both 
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metrics are relatively close and/or identical to each other. On the other hand, if the ranking 
for one metric is considerably different than the other, than this person would be deemed 
discordant. Discordance status (i.e. being concordant or discordant) is then used to estimate 
risk for subclinical and clinical CVD.  
Many studies have examined the association of LDL discordance (LDL-C/LDL-P) 
on cardiovascular risk15, 17-23, with only one study also examining the association of HDL-
C/HDL-P discordance with CVD risk.17 The general consensus regarding LDL is that in 
concordant groups, both LDL-C and LDL-P equally predict risk. In the case of discordant 
LDL-C/LDL-P, risk of adverse cardiovascular outcomes tracks more so with LDL-P, with 
increased LDL-P levels indicating higher risk.18, 19 In the single study examining HDL 
discordance, discordance between HDL-P and HDL-C (percentage difference) was not a 
significant predictor of incident CHD or CVD events in three separate groups of 
participants (metabolic syndrome without diabetes, diabetes mellitus, neither metabolic 
syndrome nor diabetes mellitus), however, in the entire sample, higher levels of HDL 
discordance (higher HDL-P and lower HDL-C) were associated with lower CHD and CVD 
risk.17 While much of the literature on lipoprotein discordance focuses on clinical and 
subclinical indices of CVD, no studies have examined the longitudinal associations of 
either LDL or HDL discordance with incident metabolic syndrome (MetS) or type 2 
diabetes (T2D), important risk factors for CVD. 
Exercise is well known to improve the lipoprotein profile, including increases in 
HDL-C and large HDL-P concentrations, along with decreases in small LDL-P 
concentration and increases in LDL particle size.24, 25 However, the effects of regular 
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exercise on LDL and HDL discordance is unknown, as well as how baseline discordance 
status is associated with exercise induced changes in CVD risk factors. 
Therefore, the present study proposes to analyze the cross-sectional and 
longitudinal associations of LDL and HDL discordance with CVD risk factors and risk of 
MetS and T2D in the Coronary Artery Risk Development in Young Adults (CARDIA) 
Study cohort study (N=3891). Additionally, we intend to examine the effect of baseline 
discordance status on changes in multiple CVD risk factors in two exercise intervention 
studies: the HEalth, RIsk factors, exercise Training And GEnetics (HERITAGE) Family 
Study (N=715) and the Health Benefits of Aerobic and Resistance Training in individuals 
with type 2 diabetes (HART-D) study (N=214). These goals will be addressed through the 
following aims. 
Aims 1 and 2 
Aim 1 will evaluate the cross-sectional relationship between LDL and HDL 
discordance status and multiple cardiovascular risk factors (resting blood pressure [BP], 
fasting blood glucose [FBG], fasting insulin, C-reactive protein levels [CRP], physical 
activity levels [PA], cardiorespiratory fitness [CRF], and multiple NMR based lipoprotein 
subclass traits). 
Aim 2 will examine the association between discordance status and incident T2D, 
or incident MetS over 23 years of follow. Both aims will analyze data from the CARDIA 
Study. 
For both aims, Year 7 data from the CARDIA study will be used to classify LDL 
and HDL based lipoprotein discordance status via two methods: 1) Median based 
discordance, 2) Continuous discordance 
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For median based discordance, separate categorical discordance groups will be 
made for LDL and HDL by denoting LDL-C, LDL-P, HDL-C, and HDL-P values greater 
than or equal to the race- and sex-specific median value as high and below the median as 
low. Four exclusive cholesterol/particle discordant groups will be made for both LDL and 
HDL from these base categories: 1) low/low (below the median for both cholesterol content 
and particle concentration), 2) low/high (below the median for cholesterol content, at or 
above the median for particle concentration), 3) high/low (at or above the median for 
cholesterol content, below the median for particle concentration), and 4) high/high (at or 
above the median for both cholesterol content and particle concentration). 
Lipoprotein cholesterol and particle concentrations will be rank ordered into race- 
and sex-specific percentiles to establish continuous discordance status. Continuous 
discordance will then be defined by subtracting an individual’s lipoprotein particle 
percentile from their lipoprotein cholesterol percentile. Race- and sex-specific quartiles of 
continuous discordance will also be created and tested. 
Aim 1 Objectives 
Objective 1: Examine the relationship between a) median based lipoprotein discordance, 
b) continuous lipoprotein discordance levels and multiple cross-sectional cardiovascular 
risk factors. 
Hypothesis 1a: Those in the discordant group with low levels of LDL-C and high LDL-P 
will have the worst CVD risk factor profile relative to other LDL discordant/concordant 
groups. These participants will have the highest BP, fasting insulin, FBG, and CRP. This 
group will also have lower PA levels, CRF, and CVH. Those with the highest levels of 
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both HDL-C and HDL-P will have the most favorable CVD risk profile relative to other 
HDL discordant groups. 
Hypothesis 1b: Participants with the lower continuous LDL discordance levels (indicating 
LDL-P percentages higher than LDL-C percentages) will have worse CVD risk factor 
profiles. Participants with higher continuous HDL discordance levels (indicating HDL-P 
percentages lower than HDL-C percentages) will have worse CVD risk factor profiles. 
Aim 2 Objectives 
Objective 2: Assess the risk of incident T2D or MetS associated with baseline a) median 
based lipoprotein discordance, and b) continuous lipoprotein discordance levels  
Hypothesis 2a: Those in the discordant group with low levels of LDL-C and high LDL-P 
will have the highest risk of T2D or MetS relative to other LDL discordant/concordant 
groups. Those with the highest levels of both HDL-C and HDL-P will have the lowest risk 
of T2D or MetS relative to other HDL discordant/concordant groups. 
Hypothesis 2b: Lower continuous LDL discordance levels (indicating LDL-P percentages 
higher than LDL-C percentages) will be associated with higher risk for T2D or MetS. 
Higher continuous HDL discordance levels (indicating HDL-P percentages lower than 
HDL-C percentages) will be associated with lower risk of T2D or MetS. 
Aim 3 
Aim 3 will examine the association of baseline LDL or HDL discordance status 
with exercise induced changes in multiple cardiovascular risk factors (BP, BMI, body fat 
percentage, FBG, fasting insulin, inflammatory markers, CRF, hepatic lipase, lipoprotein 
lipase, and NMR lipoprotein subclass profiles). These relationships will be analyzed in 
participants from the HERITAGE Family study and the HART-D study. 
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Baseline LDL and HDL based lipoprotein discordance will be classified via two 
methods: 1) Median based discordance and 2) Continuous discordance as previously 
described above in aims 1 and 2. Post intervention discordance will also be classified via 
continuous discordance. 
Aim 3 Objectives 
Objective 3.1: Examine the relationship between baseline a) median based lipoprotein 
discordance (HERITAGE), and b) continuous lipoprotein discordance levels (HART-D) 
and exercise induced changes in CVD risk factors. 
Hypothesis 3.1a: Those in the discordant group with low levels of LDL-C and high LDL-
P will experience the largest improvements in CVD risk factors relative to other LDL 
discordant/concordant groups. Also, those with the lowest levels of both HDL-C and HDL-
P (concordantly low HDL) will experience the largest improvements in CVD risk factors 
relative to other HDL discordant/concordant groups. 
Hypothesis 3.1b: Continuous LDL discordance levels will be inversely associated with 
improvements in CVD risk factors. Those who have lower LDL discordance levels 
(indicating LDL-P percentages higher than LDL-C percentages) will see increased benefit 
of exercise relative to higher LDL discordance levels. Continuous HDL discordance levels 
will be positively associated with improvements in CVD risk factors. Those who have 
higher HDL discordance levels (indicating HDL-C percentages higher than HDL-P 
percentages) will experience increased benefit of exercise relative to lower HDL 
discordance levels. 
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Objective 3.2: Examine whether exercise induced changes in continuous lipoprotein 
discordance differs between baseline median based lipoprotein discordance groups 
(HERITAGE) 
Hypothesis 3.2: Those in the discordant group with low levels of LDL-C and high LDL-
P will experience the largest improvements in continuous lipoprotein discordance levels, 
becoming more concordant with lower LDL-P, relative to other LDL 
discordant/concordant groups. Also, those in the discordant group with the low HDL-C and 
high HDL-P will experience the largest improvements in continuous lipoprotein 
discordance levels, becoming more concordant with increased HDL-C, relative to other 
HDL discordant groups. 
These studies will likely be the first to examine the longitudinal relationship 
between lipoprotein cholesterol/particle discordance and either T2D or MetS. While 
studies have found cross sectional associations between lipoprotein discordance and both 
T2D and MetS18, 22, none have examined if discordant conditions manifest before the onset 
of either T2D or MetS. Similarly, we will be the first to examine the relationship between 
HDL discordance and either condition. 
Furthermore, no studies have explored the association between lipoprotein 
discordance and exercise induced changes in CVD risk factor profiles. Assessment of this 
relationship may provide valuable information for the prescription of exercise as a 
treatment or preventive measure for CVD and other related chronic conditions. 
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CHAPTER 2 
LITERATURE REVIEW 
LDL, HDL and CVD Risk 
 Both LDL-C and HDL-C have been thoroughly investigated as major contributors 
to atherogenesis and CVD. Numerous studies show that LDL-C and HDL-C are among the 
strongest, independent risk factors for CVD, with LDL-C being positively associated and 
HDL-C being inversely associated with CVD risk.1-6, 26, 27 Collective data of over 170,000 
participants from 26 randomized statin treatment trials reveals a 22% reduction in one year 
risk of major vascular event per mmol/L (38.67 mg/dL) reduction of LDL-C.7 
Nevertheless, an average of 9% of treated patients from prospective studies of optimal 
statin therapy still experience major CVD events, representing a considerable residual risk.8 
Analysis from the Framingham study showed a 2.5% lower 12 year CHD risk per mg/dL 
of HDL-C at baseline. Clinical trials aimed at increasing HDL-C levels, however, have not 
improved CVD outcomes despite significant increases in HDL-C.9-12 These findings have 
led to the investigation of alternative lipoprotein measurements as cholesterol content alone 
may not fully encompass LDL and HDL related disease risk. 
 Both LDL and HDL are largely heterogeneous particles varying in size, density, 
and composition. The advent of NMR and other lipoprotein subclass analyses have allowed 
for incorporation of these alternative lipoprotein traits in chronic disease risk assessment. 
One popular risk assessment alternative to cholesterol is lipoprotein particle concentration. 
Lipoprotein particle concentration represents the respective number of LDL or HDL 
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particles present, while cholesterol content is representative of the amount of cholesterol 
carried by these particles. When comparing particle and cholesterol indices, total LDL-P 
has been shown to have stronger associations with both subclinical disease13 and CVD 
events14, 15 than LDL-C, with increased LDL-P levels associated with higher risk. Analysis 
from the Framingham Offspring Study shows a 28% increased risk of incident CVD (HR 
1.28, 95% CI 1.18 to 1.40) per standard deviation (SD) increase in LDL-P, while each SD 
increment in LDL-C was only associated with an 11% risk increase over a median follow 
up of 14.8 years.15 Furthermore, among the placebo arm of the Jupiter trial, baseline LDL-
P (HR 1.21 per standard deviation [SD] higher, 95% CI 1.07 to 1.37) and not LDL-C (HR 
1.03, 95% CI 0.88 to 1.21) was associated with incident CVD events over a 1.9 year median 
follow up.28 Similar analysis from the MESA cohort compared quartiles of HDL-C and 
HDL-P in predicting risk of incident CHD over a mean of 6 years follow up.16 In comparing 
the highest quartile to the lowest, the authors found total HDL-P (HR 0.49, 95% CI 0.27 to 
0.86), but not HDL-C (HR 0.92, 95% CI (0.48 to 1.77), to have an independent inverse 
association with coronary heart disease (CHD) and subclinical disease, when both HDL-P 
and HDL-C were included in the model.16 Analyses like these that use both cholesterol 
content and particle concentration in risk prediction separately in statistical models, treat 
them as independent predictors. However, because both LDL-C and HDL-C are not 
biologically independent of their particle concentrations, treating cholesterol content and 
particle concentration as independent predictors does not account for both the biological 
similarities represented by each variable.29  
As opposed to treating cholesterol content and particle concentration as 
independent predictors of risk, recent literature has employed lipoprotein discordance 
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analysis to account for both the biological similarities and differences represented by each 
variable. Lipoprotein discordance analyses generally use standardized lipoprotein 
cholesterol concentrations and compare them to another lipoprotein metric such as particle 
concentration (e.g., LDL-C/LDL-P). From this ratio, a level of concordance/discordance 
can be derived, representing the relative similarity between an individual’s cholesterol and 
particle concentration measures. This similarity is gauged by ranking individuals within a 
study cohort by their cholesterol levels and particle concentrations separately. Individuals 
are deemed concordant if their rankings for both metrics are relatively close and/or 
identical to each other. Conversely, if the ranking for one metric is considerably different 
than the other, than this person would be deemed discordant. Discordance status (i.e. being 
concordant or discordant) is then used to estimate risk for adverse outcomes of concern. 
For the intents and purposes of this review, the focus was literature examining 
discordance between cholesterol content and particle concentration (or a particle 
concentration surrogate) of both LDL and HDL. Several studies examining LDL based 
discordance have used apoB as their particle concentration measure while others have used 
direct measurement of LDL-P from methods such as NMR analysis or vertical auto profile 
testing. ApoB is the primary protein constituent of atherogenic lipoproteins which consist 
of chylomicron remnants, very low density lipoproteins, intermediate density lipoproteins, 
LDL, and lipoprotein(a).30 ApoB is present in these lipoproteins at one molecule per 
particle, thus being an indicator for particle concentration. Because the large majority of 
apoB molecules reside within LDL particles (generally over 90%), apoB and LDL-P 
concentrations may generally be treated as operationally equivalent.31 In the case of HDL, 
the primary protein on these particles, apoA-1, is present in varied amounts per particle. 
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Thus, apoA-1 is not as reliable an estimate of HDL-P concentration as apoB is for LDL-P 
and direct measurements of HDL-P are more appropriate. 
Methods of Defining Lipoprotein Discordance 
Of the studies examining discordance between lipoprotein cholesterol content and 
particle concentration, there are multiple methods used to define discordance. The methods 
employed in the literature on LDL or HDL cholesterol/particle discordance include: 
Median based, percentile based (continuous or categorical), residual based, and quartile 
based.  
Median Based Discordance.  
Median based discordance studies establish high and low groups of both cholesterol 
content and particle concentration based upon the median value in the study population. 
Separate categorical discordance groups are created by denoting LDL-C, LDL-P, HDL-C, 
and HDL-P values greater than or equal to median value as high and below the median as 
low. Four particle/cholesterol groups are then made via these classifications 1) low/low 
(below the median for both particle concentration and cholesterol content), 2) low/high 
(below the median for particle concentration, at or above the median for cholesterol 
content), 3) high/low (at or above the median for particle concentration, below the median 
for cholesterol content), and 4) high/high (at or above the median for both particle 
concentration and cholesterol content).  
In an analysis of the Framingham offspring cohort, Cromwell et al. (2007) found 
that 21% of those with low LDL-C were discordant with high levels of LDL-P. Over a 
median follow up of 14.8 years, this discordant group (high LDL-P/low LDL-C) had an 
increased CVD event rate (85 per 1000 person years) relative to the group with low LDL-
 
12 
C and LDL-P levels (65 per 1000 person years), thus showing that regardless of LDL-C 
levels, high LDL-P is associated with increased CVD risk. 15 
Similar median based analysis from the Women’s Health Study examined 
discordance between LDL-C and both apoB and LDL-P.19 In this study, 19% of 
participants were discordant with either high or low apoB compared to LDL-C, while 24% 
were discordant for LDL-P relative to LDL-C. Discordant groups with either low apoB or 
LDL-P were found to have the lowest prevalence of smokers, diabetics, or hypertensives. 
Furthermore, these groups had lower mean BMI and CRP levels. Among groups with 
discordantly high apoB (high apoB/low LDL-C) or LDL-P (high LDL-P/low LDL-C), 
CHD event risk over 18 years was higher than concordantly low groups (hazard ratio [HR] 
2.98, 95% confidence interval [CI] 2.41 to 3.68, p < 0.0001 for apoB; HR 2.68, 95% CI 
2.18 to 3.30, p <0.0001 for LDL-P). Opposingly, in discordant groups with low apoB (low 
apoB/high LDL-C) or LDL-P (low LDL-P/high LDL-C), CHD event risk was lower than 
concordantly high group (HR 0.31, 95% CI 0.23 to 0.41, p <0.0001 for apoB; HR 0.39, 
95% CI 0.31 to 0.48, p <0.0001 for LDL-P).19 The authors conclude that, in women with 
discordant LDL measures, CHD risk may be underestimated or overestimated if LDL-C 
alone is used. 19 Therefore, people with discordantly low LDL particle metrics (low LDL-
P/high LDL-C) would have their risk overestimated by LDL-C while CHD risk for those 
with discordantly high LDL particle metrics (high LDL-P/low LDL-C) would be 
underestimated. 
Wilkins et al. (2016) examined the development of coronary artery calcification 
(CAC) among LDL discordant groups in the CARDIA cohort. 18 % of participants were 
found to be discordant between apoB and LDL-C.17 At baseline, the group with 
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discordantly high apoB had multiple CVD risk factors within normal limits (waist 
circumference, BMI, total cholesterol, LDL-C, non-HDL-C, triglycerides, HDL-C). Over 
25 years of follow up, the group with discordantly high apoB (high apoB/low LDL-C) were 
at increased odds of CAC (Odds ratio 1.55, 95% CI 1.10 to 2.18, p <0.01) relative to the 
concordantly low group (low apoB/low LDL-C). Additionally, those with discordantly low 
apoB (low apoB/high LDL-C) did not have increased odds of CAC (Odds ratio 1.29, 95% 
CI 0.91 to 1.83) when compared to the concordantly low group, showing that CAC odds 
may follow LDL-P levels as opposed to LDL-C.20 
Percentile Based Discordance.  
Percentile-based discordance can be used in a continuous or categorical manner. In 
the case of continuous percentage-based discordance, both the lipoprotein concentrations 
and cholesterol content of the study sample are rank ordered into percentages. The 
difference in percentage between particle concentration and cholesterol content is then used 
as a continuous variable to predict outcomes. Alternatively, studies have determined a 
specific cutoff percentage difference that is deemed as discordant. In this case three 
categorical groups are made with one concordant group, another discordant with particle 
concentration being higher than cholesterol content, and a second discordant group where 
particle concentration is less than that of cholesterol content. 
Otvos et al (2011) examined the association of percentile based (categorical) 
discordance in the MESA cohort with cross sectional carotid intima media thickness as 
well as incident CVD events. The authors chose a cutoff of ±12 % difference between 
LDL-P and LDL-C to be classified as discordant. This difference was chosen to assure that 
50 % of the population tested was classified as discordant (25% with LDL-P > LDL-C and 
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25% with LDL-P < LDL-C).  The discordant group with LDL-P > LDL-C had a higher 
proportion of metabolic syndrome, obese, Hispanics, and males relative to the concordant 
group. This same group also had the lowest mean LDL particle size and highest carotid 
intima media thickness. Cox regression analysis revealed that, among discordant groups, 
LDL-P (HR 1.41, 95% CI 1.15 to 1.75, p = 0.001) and not LDL-C (HR 1.17, 95% CI 0.96 
to 1.42, p = 0.13) was a significant predictor of incident CVD events over a mean follow 
up of 5.5 years.18 
In the only study on adolescents, Mietus-Snyder et al. (2013) examined cross 
sectional CVD risk factor profiles amongst groups of sixth grade students in the 
HEALTHY primary prevention trial with discordant levels of LDL-P relative to LDL-C. 
Categorical percentage-based discordance was used with a cutoff of ± 20 % difference 
between LDL-P and LDL-C to classify discordance. This cutoff produced a 34 % overall 
discordance rate. No difference in fasting glucose was found between groups, however, the 
discordant group with LDL-P > LDL-C had significantly higher insulin and HOMA-IR 
levels relative to concordant and LDL-P < LDL-C groups (Bonferroni P ≤0.05 between all 
groups). The same LDL-P > LDL-C group also had worse CVD risk factor profiles outside 
of insulin resistance. This group had increased mean BMI, triglycerides, very large density 
lipoprotein particle concentration, and lower HDL-C and HDL-P levels compared to both 
other groups (Bonferroni P ≤0.05 between all groups).21 This study highlights that 
discordant phenotypes and their associated risk factors may begin to manifest early in life. 
Tehrani et al. (2016), similar to Otvos, also examined lipoprotein 
cholesterol/particle discordance in the MESA cohort, however groups were further 
categorized by metabolic syndrome status. Continuous percentile-based discordance 
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analysis was performed on the entire study population for both HDL and LDL, after which 
participants were separated into one of three groups: 1) MetS without T2D, 2) T2D, or 3) 
Neither MetS nor T2D. Mean LDL percent discordance differed between diseased and non-
diseased groups, however MetS and T2D groups did not differ. Mean HDL discordance 
percent was significantly different between all groups. Investigations into the association 
between lipoprotein discordance and incident CHD or CVD events revealed that higher 
levels of LDL discordance (increased LDL-P and decreased LDL-C) were associated with 
increased risk of both CHD (HR, 1.21 95% CI 1.01 to 1.47, p <0.05) and CVD (HR 1.26, 
95% CI 1..07 to 1.47, p <0.05) in the MetS group only. HDL discordance was not predictive 
of either CHD or CVD in any of the study groups, however, in the entire sample, higher 
levels of HDL discordance (increased HDL-P and decreased HDL-C) were associated with 
lower CHD (HR 0.90, 95% CI 0.81 to 1.00, p <0.05) and CVD (HR 0.90, 95% CI 0.83 to 
0.99, p <0.05) events.17 Findings from this study highlight that the association between 
lipoprotein discordance with CVD may differ by chronic disease status. 
Residual Based Discordance.  
Residual based discordance uses linear regression to predict particle concentration 
based on cholesterol content. Discordance status is then based on the difference in true 
particle concentration versus expected concentration from regression analysis.  
Pencina et al. (2015) examined the association of residual based discordance and 
incident CHD in the Framingham Offspring cohort over 20 years of follow up. Expected 
apoB concentrations based on LDL-C were expressed via linear regression. The difference 
between measured and expected apoB was calculated, separated into tertiles and used in 
Cox regression models to investigate the relationship between apoB discordance and risk 
 
16 
of CHD. In the third tertile, where apoB was higher than expected, there were more men 
and participants were older with decreased HDL-C and increased BMI and triglycerides 
relative to lower tertiles. Furthermore, this group had increased proportions of 
hypertensives and metabolic syndrome. Cox regression analysis revealed that the lowest 
tertile (apoB lower than expected) was at lower risk of CHD (HR 0.70, 95% CI 0.51 to 
0.96), while the highest tertile was at an increased risk (HR 1.46, 95% CI 1.14 to 1.86) 
relative to the middle tertile (apoB ≈ expected).22 Similar to other studies on LDL 
discordance, Pencina et al. (2015) show that lower LDL particle concentrations, as 
represented by apoB, are associated with more favorable outcomes relative to high 
concentrations. 
Quintile Based Discordance.  
Quintile based discordance separates both cholesterol content and particle 
concentrations of study participants into quintiles. Having a particle concentration quintile 
a set amount away (1 quintile or more) from the same persons cholesterol quintile is 
deemed as being discordant. 
Analysis from the Quebec Cardiovascular Study examined the association between 
quintile based apoB/LDL-C discordance and coronary artery disease (CAD) risk. 
Participants were separated into quintiles based on both apoB and LDL-C separately. 
Discordance was classified as having a quintile for apoB that was one or more quintiles 
different than that of LDL-C. This method produced a 51% discordance rate between apoB 
and LDL-C. Discordantly high apoB (apoB quintile > LDL-C quintile) was associated with 
increased BMI and triglycerides as well as lower HDL-C and LDL-P size relative to those 
discordantly low for apoB (apoB quintile < LDL-C quintile). Cox proportional hazard 
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models compared two discordant groups (apoB > LDL-C and apoB < LDL-C) to the group 
of participants concordant in quintile one (lowest apoB and LDL-C levels). Both the 
discordantly high and discordantly low apoB groups  were found to be at an increased 5 
year risk for CAD with a hazard ratio of 3.2 (95% CI 1.2 to 8.1, p = 0.02) for discordantly 
high apoB and 3.0 (95% CI 1.1 to 7.8, p = 0.03) for discordantly low apoB.23 Findings from 
this study suggest that having both low apoB and low LDL-C may be ideal for minimizing 
LDL related CAD risk. 
Conclusion 
The general consensus from the literature is that higher levels of apoB or LDL-P 
are associated with increased risk of CVD. Cross sectionally, increased apoB or LDL-P 
levels are associated with adverse CVD risk factor profiles. These risk factor differences  
have been found as early as adolescence, where those with LDL-P  > LDL-C showed 
increased insulin resistance and BMI among other factors.21 Median based analysis from 
the Women’s Health Study shows that in discordant groups, CVD risk tends to track with 
particle indices rather than cholesterol content.19 Thus, someone with high levels of  LDL-
C but low levels of LDL-P may be at lower risk for future CVD events than their LDL-C 
would reflect. This is somewhat supported by data from the CARDIA study where those 
discordantly low for apoB (low apoB/high  LDL-C) did not have increased odds of CAC 
when compared to the concordantly low group (low apoB / low LDL-C).20 
When it comes to HDL discordance, only one study investigated the association between 
HDL-P / HDL-C discordance and CVD events using data from the MESA cohort. 
Participants were broken into three groups based on metabolic syndrome status and 
continuous HDL discordance levels were not predictive of future CVD events in any of the 
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groups. However, in combined analysis, increased levels of HDL discordance (higher 
HDL-P / lower HDL-C) was associated with lower CVD risk. Clearly, further research on 
HDL discordance and CVD is needed to form a general consensus. 
Literature Limitations 
While much of the literature on discordance between particle indices and 
cholesterol content focuses on CVD risk or cross-sectional risk factor profiles, none have 
examined the longitudinal associations between these conditions and MetS or T2D. 
Because both MetS and T2D are widely accepted risk factors for CVD it may be important 
to know if lipoprotein imbalances between particle indices and cholesterol content manifest 
before these chronic conditions. Furthermore, the literature on HDL-P / HDL-C 
discordance and chronic disease is sparse. 
Exercise also plays a considerable role in CVD risk and the progression of CVD 
risk factors. Multiple studies support exercise as a preventive measure, aiding in achieving 
more favorable CVD risk profiles and lower levels of chronic diseases, however, no prior 
studies have examined how discordance between lipoprotein particles and their cholesterol 
content may affect exercise induced changes in CVD risk factors. 
Thus, the present study proposes to analyze the cross sectional and longitudinal 
associations of LDL and HDL discordance with CVD risk factors and risk of MetS and 
T2D in CARDIA Study cohort. Additionally, we intend to examine the effect of baseline 
discordance status on changes in multiple CVD risk factors in two exercise intervention 
studies: the HERITAGE Family Study and the HART-D study. Findings from this study 
may inform future treatment for MetS and T2D as well as influence exercise prescription 
for people with discordant lipoprotein metrics
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CHAPTER 3 
GENERAL METHODOLOGY 
Aims 1 and 2 
Aim 1 will evaluate the cross-sectional relationship between LDL and HDL 
discordance status and multiple cardiovascular risk factors (BP, FBG, CRP levels, PA 
levels [exercise units], CRF, and AHA’s Life’s Simple Seven metric). Aim 2 will examine 
the association between discordance status and incident type 2 diabetes, or incident 
metabolic syndrome over 23 years of follow up. Both aims will analyze data from the 
CARDIA Study. 
Study Design 
The CARDIA study is a multicenter prospective cohort of 5115 black and white 
men and women examining the determinants of clinical and sub-clinical CVD. Participants 
aged 18-30 at baseline (year 0) were recruited from four regions in the United States: 
Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota and Oakland, 
California. Enrollment at each site was balanced by sex, age (18-24 vs. 25-30), race, and 
education. Follow up was performed at years 2, 5, 7, 10, 15, 20, 25, and 30 with retention 
rates of 90%, 86%, 81%, 77%, 74%, 72%, 72%, and 71%, respectively. Our analysis 
employed data from years 7 to 30 of the study. Additional details on design and recruitment 
for the study have been previously published.32 Approval from institutional review boards 
was obtained annual by each field, and participants provided informed consent at each 
exam
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Measurements 
Standardized protocols were used at each center across all examinations. 
Participants were asked to fast for at least 12 h before each examination and avoid smoking 
or heavy physical activity (PA) at least 2 h prior. 
Anthropometrics. Height and weight were measured at each examination while 
wearing no shoes and light examination clothing. Height was measured via vertical ruler 
to the nearest 0.5 cm and weight to the nearest 0.2 kg with a calibrated balance beam scale. 
BMI was calculated as weight in kg divided by height in meters squared.  
Blood pressure was measured by trained technicians after participants had rested for 5 
minutes using and random zero sphygmomanometer (years 7 through 20). Year 25 and 30 
blood pressure was measured using an Omron digital blood pressure monitor. All pressures 
were measured in triplicate with the average of the final two measurements used for 
analysis. 
Fasting blood draws were taken according to standard protocol.32 Total cholesterol 
was measured via enzymatic assay. Glucose was measured via hexokinase coupled to 
glucose-6-phosphate dehydrogenase. 
Smoking status was acquired via self-report. 
Type 2 Diabetes Classification. Diabetes status at each exam was classified as a 
fasting glucose >7.0 mmol/l (126 mg/dl) or the use of oral hypoglycemic medications or 
insulin. Diabetic status was assessed in every exam from year 7 to 30. 
Metabolic Syndrome Classification. Metabolic syndrome status at each exam was 
defined as ≥ 3 of the following: (1) waist circumference >88 cm (35 in) for women and 
>102 cm (40 in) for men, (2) HDL-C <1.0 mmol/L (40 mg/dl) for men or <1.3 mmol/L (50 
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mg/dl) for women, (3) fasting triglycerides ≥ 1.7 mmol/L (150 mg/dl), (4) blood pressure 
(BP) ≥ 130 mm Hg systolic or ≥  85 mm Hg diastolic or on treatment, or (5) fasting glucose 
of 5.6 to 7.0 mmol/L (100 to 125 mg/dl). Participants reporting use of medications for 
diabetes or hypertension were also classified as having met the criterion for elevated 
glucose or blood pressure, respectively. Metabolic syndrome status was assessed in every 
exam from year 7 to 30.  
High Sensitivity C-Reactive Protein (hs-CRP).  Fasting plasma samples from 
year 7 exam were used to measure hs-CRP via a Roche latex-particle enhanced 
immunoturbidimetric assay kit. Assays were read via Roche Modular P Chemistry 
analyzer. Assay range for hs-CRP was 0.175 to 1100 μg/ml.33 Elevated hs-CRP was 
classified as a concentration greater than 3.0 mg/L. 
Cardiorespiratory Fitness (CRF). Cardiorespiratory fitness was measured via 
maximal graded treadmill testing using a modified Balke protocol at years 0, 7, and 20.34, 
35 CRF was defined as time in minutes that participants were able to walk or run on the 
treadmill. Race and sex specific CRF quartiles were established. 
Nuclear Magnetic Resonance (NMR) Lipoprotein Profiles. Lipoprotein profile 
analysis was performed on year 7 plasma samples via NMR spectroscopy at Liposcience, 
Inc. (Raleigh, NC) using the LipoProfile-3 algorithm.36 Each measurement provides 
information on lipoprotein particle concentrations such as large, medium, and small very 
low density lipoprotein (VLDL-P) and HDL-P, large and small LDL-P, and intermediate 
density lipoprotein (IDL-P). Total VLDL-P, LDL-P, and HDL-P concentrations were 
calculated by adding together their respective subclass concentrations with IDL-P factoring 
into the overall LDL-P concentration. The weighted average particle diameter for each 
 
22 
lipoprotein is calculated as the sum of the lipoprotein subclass diameters multiplied by its 
relative mass percentage as estimated from the amplitude of its methyl NMR signal. 
Parity and Gestational Diabetes Mellitus (GDM). At each examination women 
were asked if they had diabetes and if they had diabetes only during pregnancy (GDM). 
Parity was also assessed at each examination and was defined as a live birth of  >20 weeks’ 
gestation. 
Lipoprotein Discordance Classification. Year 7 data will be used to classify LDL 
and HDL based lipoprotein discordance via three methods: 1) Median based discordance, 
2) Continuous discordance, and 3) Quartiles of continuous discordance. 
For median based discordance, separate categorical discordance groups will be 
made for LDL and HDL by denoting LDL-C, LDL-P, HDL-C, and HDL-P values greater 
than or equal to the sex-specific median value as high and below the median as low. Four 
exclusive cholesterol/particle discordant groups will be made for both LDL and HDL from 
these base categories: 1) low/low (below the median for both cholesterol content and 
particle concentration), 2) low/high (below the median for cholesterol content, at or above 
the median for particle concentration), 3) high/low (at or above the median for cholesterol 
content, below the median for particle concentration), and 4) high/high (at or above the 
median for both cholesterol content and particle concentration). 
Lipoprotein cholesterol and particle concentrations will be rank ordered into sex 
specific percentiles to establish continuous discordance status. Continuous discordance 
will then be defined by subtracting an individual’s lipoprotein particle percentile from their 
lipoprotein cholesterol percentile. 
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Statistical Analysis 
Aim 1.  The cross-sectional association between LDL and HDL discordance status 
and CVD risk factors at year 7 will be assessed via multivariable linear and logistic 
regression. Separate models for median based discordance, continuous discordance, and 
quartiles of discordance will be assessed. All models will be adjusted for age, race, sex, 
BMI (except in CVH and BMI models), center, smoking status and statin usage. Linear 
regression will be used for the outcomes of moderate to vigorous PA (MVPA) level, CRF, 
BMI, blood pressure, hs-CRP, fasting glucose, and CVH.  
Aim 2.  The longitudinal association between year 7 LDL and HDL discordance 
status with incident T2D and MetS over 23 years of follow up will be assessed via Cox 
proportional hazard regression. Three separate discordance models will be examined with 
LDL or HDL discordance as independent variables: 1) median based discordance, 2) 
continuous discordance, and 3) quartiles of continuous discordance. All sex specific 
models will be adjusted for race, and the time varying covariates of age, smoking, statin 
usage, and BMI. Age and race interactions with discordance will also be examined.  
Aim 3 
Aim three will examine the effect of baseline LDL or HDL discordance on exercise 
induced changes in multiple cardiovascular risk factors (BP, BMI, body fat percentage, 
FBG, fasting insulin, CRP, CRF, hepatic lipase, lipoprotein lipase, glycA, and NMR 
lipoprotein profiles). These relationships will be analyzed in participants from the 
HERITAGE Family Study and the HART-D study. 
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Study Design: HERITAGE Family Study 
Full details of the design and methods of the HERITAGE Family Study have been 
previously reported.37 Briefly, the HERITAGE Family Study included 715 black (34%), 
and white men and women (55%) aged 17-65 years. Participants were sedentary at baseline 
with a BMI less than 40 kg/m2 and normotensive to mildly hypertensive (<160/100 
mmHg). Each participant completed a 20-week exercise intervention which consisted of 
three exercise sessions per week on a cycle ergometer. Exercise sessions started at 30 
minutes at the heart rate associated with 55% VO2max for the first two weeks and progressed 
to a target of 50 minutes at 75% of VO2max for each session, which was maintained for the 
final six weeks of training.37  
Measurements 
Anthropometrics. Height and weight were measured in duplicate to the nearest 0.1 
cm and 0.1 kg, respectively, using a stadiometer and balance beam scale. A third 
measurement was taken if the first two measurements differed by more than 0.5 cm for 
height or 200 g for weight. BMI was then calculated as weight divided by height in meters 
squared. 
Resting BP was measured using the Colin STBP-780 automated BP unit (San 
Antonio, TX) after a 5-minute rest period. Four measurements were taken with resting BP 
being reported as the mean of three or more reliable measurements. 
Blood Samples. Blood samples were collected from an antecubital vein into 
vacutainer tubes containing EDTA. Samples were taken in the morning after a 12 hour fast 
with subjects in a supine position. Samples were taken twice at baseline and 24 and 72 
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hours after the last exercise training session. For women, samples were obtained early in 
the follicular phase of the menstrual cycle.  
Lipids and Lipoproteins. Plasma very low-density lipoproteins (VLDL) were 
isolated via ultracentrifugation. HDL fractions were obtained after precipitation of LDL in 
the infranatant by the heparin-manganese chloride method. Total cholesterol and 
triglyceride levels were determined in plasma and lipoproteins via enzymatic methods 
(Technicon RA- 500 Analyzer; Bayer Corporation Inc., Tarrytown, NY). 
Fasting Glucose and Insulin. An intravenous glucose tolerance test was 
administered in the morning after an overnight fast. Blood samples were collected through 
a venous catheter from an antecubital vein to determine plasma glucose and insulin. Plasma 
glucose was measured enzymatically38, while plasma insulin was measured via 
radioimmunoassay with polyethylene glycol separation.39 
Lipoprotein Lipase and Hepatic Lipase. Plasma lipoprotein lipase (LPL) and 
hepatic lipase (HL) were measured after a 12-hour overnight fast and 10 minutes after 
intravenous injection of heparin (60 IU/kg body weight). Post heparin lipase activities were 
measured as previously described.40 Lipolytic enzyme activities were expressed as 
nanomoles of oleic acid released per milliliter of plasma per minute. 
High Sensitivity C-Reactive Protein (hs-CRP). Plasma hs-CRP was measured at 
baseline and after the 20-week exercise training program via a high-sensitivity solid-phase 
chemiluminescent immunometric assay (IMMULITE 2000 High Sensitivity CRP, 
Diagnostic Products Corporation, Los Angeles, CA) implemented on an automated 
immunoassay instrument (Diagnostic Products Corporation, Los Angeles, CA). In a 
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sample of 48 blind duplicates, the intra-class correlation was 0.98 and the coefficient of 
variation was 6.4%.41 
Lipoprotein Subclass Profiles and GlycA. Comprehensive lipoprotein profiling 
and GlycA analysis was performed on baseline and post-training plasma samples via NMR 
spectroscopy at Liposcience, Inc. (Raleigh, NC) using the LipoProfile-3 algorithm.36 Each 
profile measurement provides information on lipoprotein particle concentrations such as 
large, medium, and small very low density lipoprotein (VLDL-P) and HDL-P, large and 
small LDL-P, and intermediate density lipoprotein (IDL-P). NMR signal amplitudes 
originating from the N-acetyl methyl group protons of N-acetylglucosamine residues on 
the glycan branches of glycoproteins were used to quantify GlycA concentrations. GlycA 
in a systemic inflammatory marker that has been associated with incident CVD, 
independent of traditional risk factors.42-46  
Maximal Oxygen Consumption (VO2max). VO2max was measured via two 
maximal exercise tests, on separate days before and after the 20-wk training program. Tests 
were administered via a cycle ergometer (model 800S, SensorMedics, Yorba Linda, CA) 
connected to a metabolic cart (model 2900, SensorMedics). An electrocardiogram machine 
was used to monitor heart rate. During each exercise stage, gas exchange variables (O2 
uptake, CO2 output, minute ventilation, and respiratory exchange ratio) were recorded as a 
rolling average of three 20-s intervals. The criteria for VO2max were as follows: respiratory 
exchange ratio >1.1, plateau in O2 uptake (change of <100 ml/min in the last 3 consecutive 
20-s averages), and a heart rate within 10 beats/min of the maximal level predicted by age. 
All subjects achieved at least one of the VO2max criteria before and after training. The 
 
27 
majority of the exercise tests were conducted at the same time of day, with at least 48 h 
between tests. 
To adjust for differential body sizes and fitness levels, the initial power output for 
the first maximal test was 40–50 watts for 3 minutes followed by increases of 10–25 watts 
at 2-minute intervals until volitional exhaustion. During the second maximal test, subjects 
exercised for 8 – 12 minutes at 50 watts, 8–12 minutes at 60% VO2max, and 3 minutes at 
80% VO2max. In the case that 50 watts was >60% VO2max, the power output associated with 
60% was done first followed by 50 watts. The resistance was then increased to the highest 
power output attained in the first maximal test. If subjects were able to pedal after 2 
minutes, power output was increased every 2 minutes thereafter until volitional fatigue. 
The average VO2max from these two tests was taken as the VO2max for that subject if both 
values were within 5% of each other. If they differed by more than 5%, the higher VO2max 
value was then used. Reproducibility of VO2max in these subjects was examined and 
characterized by an intraclass correlation coefficient of 0.97 for repeated tests with a 
coefficient of variation of 5%.47 
Body Composition Measurements. Body density and body fat percentage were 
determined by underwater weighing.48 Reproducibility of the body density, fat mass, and 
pulmonary residual volume measurements was high, with intraclass correlation 
coefficients between 0.97 and 1.00. There were no differences in reproducibility among 
the four clinical centers.48 Visceral adipose tissue was measured using computed axial 
tomography at the level of the intervertebral disc between lumbar vertebrae 4 and 5.49  
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Study Design: HART-D Study 
The HART-D study included 214 sedentary (54.7% White, 40.6% Black, 3.7% 
Asian, 0.5% Hispanic, 0.5% Other) men and women (63.6%) aged 30 – 75 years with type 
2 diabetes and HbA1c levels of 6.5% to 11.0%. Participants had a BMI less than 48 kg/m2, 
blood pressure below 160/100 mm Hg, fasting triglycerides below 500 mg/dL, urine 
protein less than 100 mg/dL and serum creatinine under 1.5 mg/dL. Further exclusion 
criteria included use of an insulin pump, history of stroke, advanced neuropathy or 
retinopathy, or any serious medical condition that prevented participants from adhering to 
the protocol or exercising safely. 
HART-D was a nine-month exercise intervention with a control group and three 
exercise training groups: aerobic exercise training only (AT), resistance exercise training 
only (RT), and a combination of aerobic and resistance training (AT/RT). The non-exercise 
control group was asked to maintain their normal level of activity during the 9 months and 
were offered weekly stretching and relaxation classes. 
The AT group exercised three to five days/week at an intensity of 50–80% of their 
VO2max for a total dose of 12 kcal/kg/week. Caloric expenditure was adjusted weekly based 
upon weight changes. American College of Sports Medicine equations were used to 
calculate caloric expenditure and therefore time required per exercise session. 
The RT group trained 3 days/week. Each session included two sets of four upper 
body exercises (chest press, lateral pull-down, military press, and seated row), three sets of 
three lower body exercises (leg press, leg ex- tension, and hamstring curl), and two core 
exercises (abdominal crunches and back extensions). Each set consisted of 10-12 
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repetitions. The prescribed weight was increased when participants could complete 12 
repetitions on the last set of each exercise for two consecutive sessions. 
The AT/RT group was prescribed 3 days/week of aerobic exercise at a dose of 10 
kcal/kg/week and 2 resistance training sessions per week. Resistance exercises and their 
progression were the same as those in the resistance training only group, however, only 
one set of each exercise was performed.  
Measurements 
All measurements were taken at baseline and at one of two follow up visits. Follow 
up visit one occurred between 48 and 96 hours following the final exercise session. 
Similarly, the second follow up visit occurred between 48 and 96 hours following follow 
up visit one. 
Anthropometrics. Height was measured via a standard stadiometer and weight 
was measured on a GSE 450 electronic scale (GSE Scale Systems, Novi, Michigan). BMI 
was calculated as weight in kg divided by height in meters squared.   
Blood Samples. Blood samples were collected via venipuncture after a minimum 
10-hr fast. Post intervention samples were collected within 48 to 96 hours of the final 
exercise bout.  
Lipids and Lipoproteins. Fasting blood lipids (total cholesterol, LDL-C, HDL-C, 
and triglycerides) were analyzed on a DXC 600 Pro (Beckman Coulter Inc, Brea, 
California). 
Fasting Glucose and Insulin. Glucose was measured on a DXC 600 Pro (Beckman 
Coulter Inc, Brea, California). Insulin was measured via immunoassay on a Siemens 2000 
(Siemens, Deerfield, Illinois). 
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High Sensitivity C-Reactive Protein (hs-CRP). Plasma hs-CRP at baseline and 
post intervention was measured using a solid phase chemiluminescent immunometric assay 
on Immulite 2000 analyzer (Siemens, Deerfield, Illinois) Samples were stored at −80 C° 
and analyzed at the conclusion of the HART-D trial.  
Body Composition Measurements. Body composition was measured via dual-
energy x-ray absorptiometry scans performed on a QDR 4500A whole-body scanner 
(Hologic Inc, Bed- ford, Massachusetts).  
Lipoprotein Subclass Profiles and GlycA. Comprehensive lipoprotein profiling 
and GlycA analysis was performed on baseline and post-training plasma samples via NMR 
spectroscopy at Labcorp, Inc. (Morrisville, NC) using the LipoProfile-4 algorithm.36 Each 
profile measurement provides information on lipoprotein particle concentrations such as 
very large, large, medium,  small and very small triglyceride rich lipoprotein and large, 
medium, and small HDL-P and LDL-P. NMR signal amplitudes originating from the N-
acetyl methyl group protons of N-acetylglucosamine residues on the glycan branches of 
glycoproteins were used to quantify GlycA concentrations. 
Maximal Oxygen Consumption (VO2max). VO2max was measured via maximal 
exercise tests conducted on a treadmill (Trackmaster 425, Carefusion, Newton, Kansas) 
with respiratory gases sampled through a True Max 2400 Metabolic Measurement Cart 
(ParvoMedics, Salt Lake City, Utah). A modified Balke protocol was used for the maximal 
test. Participants self-selected a walking pace and the grade increased by 2% every two 
minutes until exhaustion. The same speed was used for baseline and post-intervention 
testing. 
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Lipoprotein Discordance Classification. Baseline LDL and HDL based 
lipoprotein discordance for both studies will be classified via two methods as previously 
described: 1) Median based discordance and 2) Continuous discordance. Post intervention 
discordance was also classified via continuous discordance. 
Statistical Analysis 
The association of baseline median based (HERITAGE) or continuous 
(HERITAGE and HART-D) LDL and HDL discordance status with exercise induced 
changes in CVD risk factors will be assessed via multivariable linear regression. Base 
models will be adjusted for age, race, sex, BMI and statin usage. Full models will 
additionally be adjusted for baseline trait (i.e. adjusting for baseline BMI when assessing 
for changes in BMI). HART-D models will additionally be adjusted for training group 
assignment with the interaction between discordance and group assignment also being 
explored. 
The association of baseline median based (HERITAGE) or continuous (HART-D) 
LDL and HDL discordance status with exercise induced changes in continuous discordance 
status will also be assessed via multivariable linear regression. Base models will be 
adjusted for age, race, sex, BMI and statin usage. Baseline LDL discordance status will be 
used to predict changes in continuous LDL discordance while baseline HDL discordance 
status will be used to predict changes in continuous HDL discordance. HART-D models 
will additionally be adjusted for training group assignment with the interaction between 
discordance and group assignment also being explored.
 
32 
CHAPTER 4 
ASSOCIATION OF DISCORDANCE BETWEEN LOW-DENSITY LIPOPROTEIN AND 
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL VERSUS PARTICLE 
CONCENTRATION WITH THE PREDICTION OF TYPE 2 DIABETES AND 
METABOLIC SYNDROME 
 
Abstract 
Purpose: To compare cardiovascular disease (CVD) risk factor profiles among groups of 
individuals with and without discordant levels of high and low-density lipoprotein 
cholesterol (HDL-C and LDL-P respectively) compared to particle concentration (HDL-P 
and LDL-P respectively) and examine the associations between lipoprotein discordance 
status and incident type 2 diabetes mellitus (T2D) and metabolic syndrome (MetS). 
Methods: All included phenotypes were measured at the year seven exam among 3891 
participants of the CARDIA study. Sex-specific median-based lipoprotein discordance 
groups were created and combined into four exclusive cholesterol/particle groups for both 
HDL and LDL. Continuous discordance levels were created by subtracting individual 
particle percentile ranking from cholesterol percentile ranking (e.g. HDL-C – HDL-P). 
Cross-sectional associations between both median based and continuous discordance with 
baseline CVD risk factors were assessed via multivariable linear regression and partial 
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correlation, respectively. The association of incident T2D or MetS with lipoprotein 
discordance was assessed via multivariable proportional hazards regression. 
Results: Cross sectional analyses (both median and continuous) revealed that more 
favorable risk profiles (e.g. lower BMI, larger mean HDL-P, and LDL-P size) were found 
in high HDL-C groups regardless of discordance status. However, overall, discordantly 
high HDL-C (/Low HDL-P) groups displayed the most favorable profiles. Concordantly 
Low median based LDL groups displayed the most favorable risk profiles, while 
continuous LDL discordance was most strongly associated with LDL subclass measures 
(r=0.51 for mean LDL-P size; r=-0.50 for small LDL-P concentration; p<0.0001 for both). 
In women only, both HDL and LDL discordance were associated with T2D and MetS risk, 
with higher risk being associated with lower HDL-C (Low HDL-C/High HDL-P at highest 
risk of T2D) and higher LDL-P (Low LDL-C/High LDL-P at highest risk of MetS). Race 
specific associations were found for median based LDL discordance with T2D risk (Black 
women only) and continuous HDL discordance with MetS risk (Whites only).  
Conclusions: Lipoprotein discordance is associated with differences in CVD risk factor 
profiles, with more favorable risk factor profiles generally being found in those with high 
HDL-C or low LDL-P. Lipoprotein concordant/discordant status is a significant risk 
factor for both T2D and MetS in women only, although racial disparities may be present. 
These data support the regular measurement of lipoprotein particle concentrations 
alongside of cholesterol measures in chronic disease management and prevention. 
Introduction 
A large body of evidence supports a positive association between  low-density 
lipoprotein cholesterol (LDL-C) and cardiovascular disease (CVD) 1-3, while  high-density 
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lipoprotein cholesterol (HDL-C) levels are inversely related with CVD.3-6 However, Many 
patients with well controlled LDL-C still have considerable residual CVD risk.8 
Furthermore, randomized controlled trials with niacin or inhibitors of cholesterol ester 
transfer protein have not improved CVD outcomes despite significant increases in HDL-C 
levels.9-12 Both LDL and HDL are largely heterogeneous lipoproteins varying in size, 
composition, density, and function. Thus, their attributable risk may not be solely 
represented by their cholesterol content. 
Novel techniques such as nuclear magnetic resonance (NMR) spectroscopy can 
provide measurements of lipoprotein subclasses, which may provide more insight into 
potential biomarkers underlying the CVD risk associated with these particles. Total particle 
concentrations of both LDL and HDL (LDL-P and HDL-P respectively) have been shown 
to be independent risk factors for CVD, often outperforming their respective cholesterol 
contents in risk estimation.14-16 These analyses treat cholesterol content and particle 
concentration of the respective lipoproteins as separate independent predictors, however, 
this does not account for the biological similarities represented by each variable.29 
The concept of lipoprotein discordance accounts for the biological similarities and 
differences between cholesterol content and particle concentration by creating a ratio of 
the two measures in each respective lipoprotein (e.g. LDL-C/LDL-P). Individuals within a 
study cohort are ranked separately by their cholesterol content and particle concentrations 
and a level of concordance/discordance is derived, representing the relative similarity of 
their rankings for each metric. Multiple studies have evaluated LDL discordance (LDL-
C/LDL-P) based CVD risk15, 17-23 with the general consensus that both LDL-C and LDL-P 
equally predict outcomes in concordant groups (e.g. high LDL-C/high LDL-P). However, 
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in the case of discordant LDL-C/LDL-P (e.g., high LDL-C/low LDL-P), risk tracks more 
so with LDL-P, with higher LDL-P levels indicating higher risk. 18, 19 Limited literature on 
HDL discordance points to higher levels of HDL discordance (higher HDL-P and lower 
HDL-C) being associated with higher CVD risk although the relationship may be 
confounded by chronic disease status such as type 2 diabetes (T2D) or metabolic syndrome 
(MetS).17 While the body of  literature on lipoprotein discordance primarily focuses on 
clinical and subclinical indices of CVD, no studies have examined the longitudinal 
associations of either LDL or HDL discordance with incident metabolic syndrome (MetS) 
or type 2 diabetes (T2D), important risk factors for CVD.50 
Therefore, the purpose of the present study was to analyze cross-sectional CVD 
risk factor profiles and longitudinal associations of LDL and HDL discordance with risk 
of MetS and T2D in the Coronary Artery Risk Development in Young Adults (CARDIA) 
Study cohort study. 
Methods 
Study Design 
The CARDIA study is a multicenter prospective cohort of 5115 black and white 
men and women examining the determinants of clinical and sub-clinical CVD. Participants 
aged 18-30 at baseline (year 0) were recruited from four regions in the United States: 
Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota and Oakland, 
California. Enrollment at each site was balanced by sex, age (18-24 vs. 25-30), race, and 
education. Follow up was performed at years 2, 5, 7, 10, 15, 20, 25, and 30 with retention 
rates of 90%, 86%, 81%, 77%, 74%, 72%, 72%, and 71%, respectively. Our analysis 
employed data from years 7 to 30 of the study. Additional details on design and recruitment 
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for the study have been previously published.32 Approval from institutional review boards 
was obtained annually by each site, and participants provided informed consent at each 
exam. 
Measurements 
Standardized protocols were used at each center across all examinations. 
Participants were asked to fast for at least 12 h before each examination and avoid smoking 
or heavy physical activity at least 2 h prior. 
CVD risk factors. Height and weight were measured at each examination while 
wearing no shoes and light examination clothing. Height was measured via vertical ruler 
to the nearest 0.5 cm and weight to the nearest 0.2 kg with a calibrated balance beam scale. 
Body mass index (BMI) was calculated as weight in kg divided by height in meters squared. 
Waist circumference was measured as the average of two measures taken at a level midway 
between the lowest rib and iliac crest.  
Smoking status was acquired via self-report. 
Fasting blood draws were taken according to standard protocol.32 Glucose was 
measured via hexokinase coupled to glucose-6-phosphate dehydrogenase.  
Lipids and Lipoproteins. Total cholesterol and Triglycerides were determined from 
plasma via enzymatic means.51 HDL-C was determined enzymatically after dextran sulfate 
magnesium precipitations.52 LDL-C was estimated via Friedewald equation.53 
Blood Pressure. Blood pressure was measured by trained technicians after 
participants had rested for 5 minutes using a random zero sphygmomanometer (years 7 
through 20). Year 25 and 30 blood pressure was measured using an Omron digital blood 
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pressure monitor. All pressures were measured in triplicate with the average of the final 
two measurements used for analysis. 
Type 2 Diabetes Classification. Diabetes was classified as a fasting glucose >7.0 
mmol/l (126 mg/dl) or the use of oral hypoglycemic medications or insulin. Diabetic status 
was assessed in every exam from year 7 to 30. 
Metabolic Syndrome Classification. Metabolic syndrome status at each exam was 
defined as ≥3 of the following: (1) waist circumference >88 cm (35 in) for women and 
>102 cm (40 in) for men, (2) HDL-C <40 mg/dl (1.0 mmol/L) for men or <50 mg/dl (1.3 
mmol/L) for women, (3) fasting triglycerides ≥ 150 mg/dl (1.7 mmol/L), (4) blood pressure 
(BP) ≥ 130 mm Hg systolic or ≥  85 mm Hg diastolic or on treatment, or (5) fasting glucose 
of 5.6 to 7.0 mmol/L (100 to 125 mg/dl). Participants reporting use of medications for 
diabetes or hypertension were also classified as having met the criterion for elevated 
glucose or blood pressure, respectively. Metabolic syndrome status was assessed in every 
exam from year 7 to 30.  
High Sensitivity C-Reactive Protein (hs-CRP).  Fasting plasma samples from 
year 7 exam were used to measure hs-CRP via a Roche latex-particle enhanced 
immunoturbidimetric assay kit. Assays were read via Roche Modular P Chemistry 
analyzer. Assay range for hs-CRP was 0.175 to 1100 μg/ml.33  
Physical Activity (PA). Physical activity was measured via the CARDIA Physical 
Activity History questionnaire, which inquires about time spent per week among 13 
categories of PA over the past 12 months.54 A PA exercise units (EU) score was derived 
from the questionnaire, with 300 EU corresponding to the recommended 150 minutes of 
moderate physical activity per week.55 
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Cardiorespiratory Fitness (CRF). Cardiorespiratory fitness was measured via 
maximal graded treadmill testing using a modified Balke protocol at years 0, 7, and 20.34, 
35 CRF was defined as time in minutes that participants were able to walk or run on the 
treadmill. 
Parity and Gestational Diabetes Mellitus (GDM). At each examination women 
were asked if they had diabetes and if they had diabetes only during pregnancy (GDM). 
Parity was also assessed at each examination and was defined as a live birth of >20 weeks’ 
gestation. 
Nuclear Magnetic Resonance (NMR) Lipoprotein Profiles. Lipoprotein profile 
analysis was performed on year 7 plasma samples via NMR spectroscopy at Liposcience, 
Inc. (now LabCorp, Morrisville, NC) using the LipoProfile-3 algorithm.36 Each 
measurement provides information on lipoprotein particle concentrations such as large, 
medium, and small very low density lipoprotein (VLDL-P) and HDL-P, large and small 
LDL-P, and intermediate density lipoprotein (IDL-P). Total VLDL-P, LDL-P, and HDL-P 
concentrations were calculated by adding together their respective subclass concentrations 
with IDL-P factoring into the overall LDL-P concentration. The weighted average particle 
diameter for each lipoprotein is calculated as the sum of the lipoprotein subclass diameters 
multiplied by its relative mass percentage as estimated from the amplitude of its methyl 
NMR signal. 
Lipoprotein Discordance Classification. Year 7 data was used to classify LDL 
and HDL based lipoprotein discordance via three methods: 1) Median based discordance, 
2) Continuous discordance, and 3) Quartiles of continuous discordance. 
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For median based discordance, separate categorical discordance groups were made 
for LDL and HDL by denoting LDL-C, LDL-P, HDL-C, and HDL-P values greater than 
or equal to the race- and sex-specific median value as high and below the median as low. 
Four exclusive cholesterol/particle discordant groups were made for both LDL and HDL 
from these base categories: 1) Low/Low (concordantly Low: below the median for both 
cholesterol content and particle concentration), 2) Low/High (discordant: below the 
median for cholesterol content, at or above the median for particle concentration), 3) 
High/Low (discordant: at or above the median for cholesterol content, below the median 
for particle concentration), and 4) High/High (concordantly High: at or above the median 
for both cholesterol content and particle concentration). 
Lipoprotein cholesterol and particle concentrations were rank ordered into sex 
specific percentiles to establish continuous discordance status. Continuous discordance 
was then defined by subtracting an individual’s lipoprotein particle percentile from their 
lipoprotein cholesterol percentile (positive percentile indicating higher cholesterol, 
negative indicating higher particle concentration). Sex specific quartiles of continuous 
discordance were also created and tested, with quartile one representing higher particle 
concentrations and quartile four having higher cholesterol. 
Statistical Analysis 
The cross-sectional associations between median based HDL and LDL discordance status 
and CVD risk factors at year 7 were assessed via multivariable linear regression in sex-
specific models adjusted for age, race, BMI (except in anthropometric models. Partial 
correlations between continuous lipoprotein discordance and CVD risk factors were 
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assessed in the entire sample (e.g. not sex specific) and adjusted for age, sex, race, and bmi 
(except in anthropometric models).  
The longitudinal associations between year 7 LDL and HDL discordance status with 
incident T2D and MetS over 23 years of follow up were assessed via Cox proportional 
hazard regression. Three separate discordance models were examined with LDL or HDL 
discordance as independent variables: 1) median based discordance, 2) continuous 
discordance, and 3) quartiles of continuous discordance. All sex specific models were 
adjusted for race, and the time varying covariates of age, smoking, and BMI.  Female-
specific models were further adjusted for time varying parity and gestational diabetes. Age 
and race interactions with discordance variables were also examined. 
Results 
Cross Sectional Analysis 
Median cutoffs for HDL-C and HDL-P were 45.00 mg/dl and 22.43 µmol/L 
respectively in men and 54.00 mg/dl and 21.86 µmol/L in women. Approximately 37% 
and 35% of men and women, respectively were concordantly low for HDL (Low HDL-
C/Low HDL-P) while 36% of men and 34% of women were concordantly high. Thus, 
about 27% of men and 31% of women had discordant levels of HDL-C and HDL-P (Tables 
4.1 and 4.2).  
In both sexes, when comparing all four HDL discordance groups at baseline, more 
favorable risk factor profiles were primarily found in the two groups that had high HDL-C 
(High HDL-C/Low HDL-P and High HDL-C/High HDL-P), regardless of discordance 
status. Both High HDL-C groups had the lowest concentrations of triglycerides and LDL-
C, while also having higher concentrations of both large HDL-P and large LDL-P which 
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contributed to higher mean HDL-P and LDL-P sizes (Tables 4.1 and 4.2). Furthermore, 
these groups displayed lower BMI and waist circumferences than their low HDL-C 
counterparts (Tables 4.3 and 4.4). In both male and female HDL discordance groups, the 
High HDL-C/Low HDL-P discordant group displayed significantly lower LDL-C, small 
LDL-P, and glycA concentrations compared to all other groups (Tables 4.1 to 4.4). 
Median cutoffs for baseline LDL-C and LDL-P were 109.0 mg/dl and 1370.50 
nmol/L respectively in men and 101.00 mg/dl and 1314.00 nmol/L respectively in women. 
Approximately 43% of both men and women were concordantly low for LDL (Low LDL-
C/Low LDL-P) while about 42% were concordantly high. Thus, around 15% of both men 
and women had discordant levels of LDL-C and LDL-P (Tables 4.5 and 4.6) 
In both sexes, across all LDL discordance groups, more favorable risk factor 
profiles were found in the two groups with the lowest LDL-P concentrations (Low LDL-
C/Low LDL-P and High LDL-C/Low LDL-P), regardless of LDL-C status. Both low LDL-
P groups had the lowest concentrations of triglycerides, small LDL-P, and glycA while 
also having the highest mean HDL-P size (Tables 4.5 to 4.8). Males with LDL discordance 
consisting of low LDL-P additionally displayed higher concentrations of HDL-C and large 
HDL-P along with lower BMI and waist circumference measures (Tables 4.5 and 4.6). In 
males, the concordantly Low group displayed significantly lower total cholesterol, LDL-
C, small HDL-P, and LDL-P concentrations than any other group, while the concordantly 
High group displayed significantly higher levels of the same traits (Table 4.5). In females, 
the concordantly Low group displayed the lowest BMI and waist circumference measures, 
as well as total cholesterol and LDL-C concentrations. The female concordantly High 
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group displayed the highest total cholesterol, LDL-C, small HDL-P, and LDL-P 
concentrations of any other group (Tables 4.6 and 4.8). 
Correlations between continuous lipoprotein discordance and CVD risk factors 
revealed that continuous discordance levels were largely indicative of respective 
lipoprotein subclass measures (Tables 4.9 and 4.10). HDL discordance was significantly 
correlated to all risk factors except CRP, having strongest correlations with small HDL-P 
concentration and mean HDL-P size (R=-0.73 and 0.66 respectively; P < 0.001. Table 4.9). 
LDL discordance was significantly correlated to all risk factors except HDL-P, large HDL-
P concentration, and diastolic blood pressure, having strongest correlations with mean 
LDL-P size and small LDL-P concentration (R=0.51 and -0.50 respectively; P,0.0001. 
Table 4.10).  
Longitudinal Analysis: Risk of Type 2 Diabetes and Metabolic Syndrome 
No main effects of baseline HDL discordance status were found for males in 
relation to T2D risk (Figure 4.1a), however, in females, both median based and continuous 
baseline HDL discordance were significant risk factors for T2D (Figure 4.1b). In median 
based analysis, the Low/High discordant group displayed significantly higher risk of T2D 
than all groups (HR: 1.72; 95% CI 1.15 to 2.59 relative to Low/Low group). No other 
significant observations were made for median based HDL discordance in females. 
Regarding continuous discordance, every percentile difference higher for HDL-C 
compared to HDL-P (i.e. higher HDL-C than HDL-P) was associated with a one percent 
lower risk of T2D (HR: 0.990; 95% CI: 0.984 to 0.997; Figure 4.1b). 
No main effects of baseline LDL discordance status were found for males in 
relation to T2D risk (Figure 4.2a), however, an interaction with race were found for 
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median based LDL discordance in females (Figure 4.2b). In median based analyses in 
black females, the concordantly High LDL group experienced significantly higher risk of 
incident T2D than all other groups (HR: 1.57; 95% CI: 1.03 to 2.40 relative to Low/Low 
group). Continuous LDL discordance was not a significant predictor of incident T2D in 
females (Figure 4.2b).  
No main effects of HDL discordance group were found for males when it came to 
MetS risk (Figure 4.3a). In females, median based HDL discordance was a significant 
predictor of incident MetS, with the High/Low discordant group displaying significantly 
lower risk of MetS than any other group (HR: 0.59; 95% CI: 0.40 to 0.88 relative to 
Low/Low group). A significant interaction was found between race and continuous HDL 
discordance in women. In white women only, each percentile difference higher between 
HDL-C and HDL-P (i.e. higher HDL-C than HDL-P) was associated with a 1.8 percent 
lower risk of MetS. (HR: 0.982; 95%CI 0.972 to 0.992; Figure 4.3b).  
In males, LDL Discordance, regardless of the specific metric used, was not a 
significant predictor of MetS risk (Figure 4.4a). In females, median based LDL 
discordance was associated with incident MetS (Figure 4.4b). In median based LDL 
discordance analysis, females in the Low/High LDL discordant group displayed 
significantly higher risk of MetS than all other groups (HR: 1.83; 95% CI: 1.18 to 2.84 
relative to Low/Low group; Figure 4.4b). 
Discussion 
Our study found cross sectional differences in multiple CVD risk factors among 
median based lipoprotein discordance groups. In HDL discordance groups, CVD risk factor 
profiles were more favorable for groups with high HDL-C while in LDL discordance 
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groups risk factors favored lower LDL-P regardless of LDL-C status. The Low/High HDL 
discordance group had the least favorable, while the High/Low HDL discordance group 
displayed the most favorable risk factor profile in both men and women. People in the 
Low/High HDL discordance group consistently (in both men and women) had the highest 
level of triglycerides, LDL-C, small HDL-P and small LDL-P while the High/Low HDL 
discordance group had the highest levels of these same traits. Similarly, the Low/High HDL 
discordance group had the lowest mean HDL-P and LDL-P sizes while the High/Low 
group had the highest mean sizes.  
Cross sectional LDL discordance analysis in both men and women showed that the 
high LDL-P groups had the least favorable risk factor profiles. No single high LDL-P group 
was consistently worse than the other. However, each high LDL-P group was significantly 
worse than both low LDL-P groups in several CVD risk factors. 
Correlational analysis revealed that continuous discordance was largely indicative 
of respective lipoprotein particle sizes (e.g. LDL discordance being most highly correlated 
with LDL-P size). Interestingly, HDL discordance displayed consistently higher 
correlations with most risk factors than that of LDL discordance. Furthermore, outside of 
HDL specific measures, waist circumference and mean LDL-P size had the next largest 
correlations with HDL discordance (both negative associations). Thus, continuous HDL 
discordance was more strongly related to the majority of metrics relative to LDL 
discordance, even outside of HDL specific traits. 
While many studies have investigated the association between LDL discordance 
and indices of CVD, 15, 17-23 none to date have examined the HDL or LDL discordance-
based risk of T2D or MetS. Furthermore, many previous studies used joint, and not sex 
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specific discordance analyses. Nevertheless, we hypothesized that our findings would 
parallel that of previous studies with higher risk favoring high LDL-P levels, regardless of 
LDL-C status. 
 In male participants, lipoprotein discordance was not associated with either T2D 
or MetS risk. In women lipoprotein discordance was significantly associated with both 
T2D and MetS incidence. HDL discordance analysis suggests that both T2D and MetS risk 
favors higher HDL-C and lower HDL-P in women. Higher continuous HDL discordance 
(higher HDL-C/lower HDL-P) was negatively associated with T2D risk and the Low 
Cholesterol/High Particle HDL discordance group (Median based) was at the highest risk 
of T2D. In terms of MetS, the High cholesterol/Low Particle HDL discordance group was 
at lowest risk. Our findings are contrary to CVD risk associations found my Tehrani et al.17 
Using data from the Multi Ethnic Study of Atherosclerosis, authors found that higher levels 
of HDL-P as opposed to HDL-C were associated with decreased risk of CVD events.17 
LDL discordance analysis in women found that black women concordantly high 
for LDL were at the highest risk of T2D. MetS risk was highest in the Low 
Cholesterol/High Particle LDL median based group. Although these findings support risk 
following that of LDL-P, they disagree in regard to LDL-C related discordance risk. 
Strengths and Limitations 
Our analysis is strengthened by the quality of the CARDIA dataset. The CARDIA 
study has used standardized, quality-controlled data collection procedures over 30 years of 
follow up with repeated exams. NMR lipoprotein subclass measurements were, however, 
only measured at a single time point in year 7 of the study, thus we were not able to measure 
changes in these measures over time, nor their association with T2D or MetS. Furthermore, 
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we did not perform race specific discordance classifications, thus possible reasoning for 
the race specific associations of discordance with either T2D or MetS are difficult to 
ascertain. 
Conclusions 
Our study found multiple cross-sectional differences in CVD risk factor profiles of 
lipoprotein discordance-based groups with continuous discordance levels being primarily 
indicative of lipoprotein sizes and concentrations of their respective lipoprotein subclasses 
(e.g. continuous HDL discordance being indicative of small HDL-P concentration). 
Median based HDL discordance revealed more favorable risk factor profiles for high HDL-
C groups while median LDL discordance groups displayed better profiles in low LDL-P 
groups. Furthermore, significant associations of lipoprotein discordance with T2D or MetS 
risk were found only in women. which may be potentially influenced by GDM and/or 
parity. While a body of work exists for LDL discordance, our study is the first to compare 
risk factor profiles among HDL discordant groups. Thus, future research should continue 
to examine the association between HDL discordance and incident CVD as well as 
different CVD risk factors in further elucidating the role of HDL in CVD
 
 
Table 4.1. Lipoprotein subclass outcomes for HDL discordant/concordant men in the CARDIA study at year seven exam 
 
  
Low HDL-C/ 
Low HDL-P  
N=650 (36.62%) 
Low HDL-C/ 
High HDL-P  
N=257 (14.48%) 
High HDL-C/ 
Low HDL-P 
N=237 (13.35%) 
High HDL-C/ 
High HDL-P 
N=631 (35.55%) 
p 
value 
Demographics            
Age 32.09 (0.14) 32.51 (0.22)c 31.72 (0.23)b 31.85 (0.14)b 0.0429 
% White 64.31 66.93 42.19 45.48 <.0001 
Continuous HDL Discordance (Percentile difference between HDL-C and HDL-P)     
Continuous HDL Discordance 1.29 (0.64)* -32.11 (1.00)* 36.84 (1.04)* -1.42 (0.64)* <.0001 
Lipid Panel,  (mg/dL)         
Total Cholesterol 173.28 (1.41)b,d 184.58 (2.19)a,c 172.88 (2.28)b,d 185.52 (1.40)a,c <.0001 
Triglycerides 119.56 (3.58)c,d 132.04 (5.58)c,d 70.87 (5.81)a,b 80.02 (3.56)a,b <.0001 
HDL-C  37.79 (0.36)* 41.83 (0.56)* 52.74 (0.58)* 58.50 (0.35)* <.0001 
LDL-C 112.45 (1.32)b,c 117.48 (2.07)* 105.55 (2.12)* 110.54 (1.30)b,c 0.001 
Lipoprotein Particle Size (nm)           
HDL-P size  8.68 (0.01)* 8.63 (0.02)* 9.15 (0.02)* 9.01 (0.01)* <.0001 
LDL-P size 20.58 (0.02)c,d 20.52 (0.03)c,d 21.03 (0.03)a,b 20.97 (0.02)a,b <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)       
Total HDL-P  20.03 (0.08)* 23.83 (0.12)* 20.95 (0.12)* 25.26 (0.08)* <.0001 
Small HDL-P  14.35 (0.10)* 17.94 (0.16)* 12.19 (0.17)* 15.90 (0.10)* <.0001 
Medium HDL-P 4.62 (0.08)c,d 4.76 (0.12)c,d 6.54 (0.13)* 7.12 (0.08)* <.0001 
Large HDL-P 1.06 (0.04)c,d 1.13 (0.06)c,d 2.23 (0.06)a,b 2.25 (0.04)a,b <.0001 
Total LDL-P 1481.60 (15.43)c,d 1501.01 (24.01)c,d 1306.05 (25.01)a,b 1361.29 (15.31)a,b <.0001 
Small LDL-P 973.82 (16.81)c,d 1012.45 (26.17)c,d 626.39 (27.26)* 697.22 (16.68)* <.0001 
Medium LDL-P 318.30 (13.54) 309.15 (21.07) 319.13 (21.95) 334.55 (13.44) 0.7362 
Large LDL-P 189.47 (7.52)c,d 179.41 (11.71)c,d 360.53 (12.20)* 329.52 (7.46)* <.0001 
a P<0.05 between low HDL-C/low HDL-P, b P<0.05 between low HDL-C/high HDL-P, c P<0.05 between high HDL-C/low 
HDL-P, d P<0.05 between high HDL-C/high HDL-P, * P<0.05 between all other groups.  
Values are presented as mean (standard error).Continuous discordance and age were assessed via univariable regression analyses. 
Race percentage was assessed via chi-square. Unless otherwise noted, all other models were adjusted for age, race, and year seven 
BMI. 
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Table 4.2. Lipoprotein subclass outcomes for HDL discordant/concordant women in the CARDIA study at year seven exam 
 
  
Low HDL-C/ 
Low HDL-P  
N=731 (34.56%) 
Low HDL-C/ 
High HDL-P  
N=343 (16.21%) 
High HDL-C/ 
Low HDL-P 
N=327 (15.45%) 
High HDL-C/ 
High HDL-P 
N=715 (33.79%) 
p 
value 
Demographics            
Age 32.06 (0.13) 32.11 (0.20) 31.87 (0.20) 32.10 (0.14) 0.781 
% White 48.02 45.19 52.29 53.71 0.0303 
Continuous HDL Discordance (Percentile difference between HDL-C and HDL-P)     
Continuous HDL Discordance 0.32 (0.63)* -35.65 (0.9)* 39.9 (0.95)* -2.19 (0.64)* <.0001 
Lipid Panel,  (mg/dL)         
Total Cholesterol 165.08 (1.15)* 179.81 (1.66)a,c 169.72 (1.74)* 182.54 (1.17)a,c <.0001 
Triglycerides 77.51 (1.86)* 92.16 (2.67)* 53.45 (2.81)* 66.74 (1.89)* <.0001 
HDL-C  44.38 (0.31)* 48.65 (0.44)* 63.08 (0.46)* 67.22 (0.31)* <.0001 
LDL-C 105.00 (1.06)* 112.43 (1.53)* 95.54 (1.60)* 101.51 (1.08)* <.0001 
Lipoprotein Particle Size (nm)           
HDL-P size  8.99 (0.01)* 8.88 (0.01)* 9.59 (0.02)* 9.35 (0.01)* <.0001 
LDL-P size 20.93 (0.02)* 20.82 (0.02)* 21.14 (0.03)* 21.03 (0.02)* <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)       
Total HDL-P  19.56 (0.07)* 23.33 (0.09)* 20.31 (0.10)* 24.53 (0.07)* <.0001 
Small HDL-P  12.05 (0.09)* 15.30 (0.13)* 10.21 (0.14)* 13.19 (0.10)* <.0001 
Medium HDL-P 5.81 (0.08)* 6.33 (0.12)a,d 6.31 (0.13)a,d 8.02 (0.09)* <.0001 
Large HDL-P 1.70 (0.04)c,d 1.70 (0.06)c,d 3.79 (0.06)* 3.32 (0.04)* <.0001 
Total LDL-P 1358.55 (12.84)b,c 1476.95 (18.45)* 1220.06 (19.41)* 1336.98 (13.06)b,c <.0001 
Small LDL-P 731.70 (13.97)b,c 881.69 (20.07)* 585.85 (21.12)* 713.57 (14.20)b,c <.0001 
Medium LDL-P 327.93 (10.62)c,d 319.43 (15.26)c,d 216.46 (16.05)a,b 221.25 (10.80)a,b <.0001 
Large LDL-P 298.92 (7.81)c,d 275.83 (11.22)c,d 417.75 (11.80)a,b 402.16 (7.94)a,b <.0001 
a P<0.05 between low HDL-C/low HDL-P, b P<0.05 between low HDL-C/high HDL-P, c P<0.05 between high HDL-C/low 
HDL-P, d P<0.05 between high HDL-C/high HDL-P, * P<0.05 between all other groups.  
Values are presented as mean (standard error).Continuous discordance and age were assessed via univariable regression analyses. 
Race percentage was assessed via chi-square. Unless otherwise noted, all other models were adjusted for age, race, and year seven 
BMI.
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Table 4.3. Cardiovascular disease risk factor outcomes for HDL discordant/concordant men in the CARDIA study at year seven exam 
 
  
Low HDL-C/ 
Low HDL-P  
N=650 (36.62%) 
Low HDL-C/ 
High HDL-P  
N=257 (14.48%) 
High HDL-C/ 
Low HDL-P 
N=237 (13.35%) 
High HDL-C/ 
High HDL-P 
N=631 (35.55%) 
p 
value 
Anthropometrics (not adjusted for BMI)         
BMI (kg/m2) 27.93 (0.18)c,d 27.92 (0.28)c,d 24.76 (0.30)a,b 25.20 (0.18)a,b <.0001 
Waist Circumference (cm) 91.82 (0.44)c,d 91.95 (0.70)c,d 83.28 (0.72)a,b 84.62 (0.44)a,b <.0001 
Cardiorespiratory Fitness (min)         
VO2max  11.24 (0.19)d 11.15 (0.30) 11.81 (0.35) 11.87 (0.20)a 0.0807 
Blood Pressure (mmHg)           
Systolic blood pressure 111.41 (0.44)b,d 114.22 (0.69)a,c 111.99 (0.72)b,d 114.04 (0.44)a,c <.0001 
Diastolic blood pressure 70.97 (0.39)b,d 73.06 (0.60)a,c 70.47 (0.63)b,d 72.18 (0.38)a,c 0.0023 
Carbohydrate Metabolism           
Glucose (mg/dL) 96.27 (0.78)c,d 97.91 (1.22)c,d 92.28 (1.27)a,b 93.07 (0.78)a,b 0.0006 
Insulin (uU/mL) 15.71 (0.58)c,d 14.80 (0.90) 13.14 (0.95)a 13.36 (0.58)a 0.0244 
Inflammatory Markers           
GlycA (µmol/L) 391.96 (2.43)c,d 385.42 (3.78)c,d 359.30 (3.93)* 375.94 (2.41)* <.0001 
C-Reactive Protein (ug/mL) 2.54 (0.17)b,d 1.54 (0.27)a 2.25 (0.28) 1.91 (0.17)a 0.0059 
a P<0.05 between low HDL-C/low HDL-P, b P<0.05 between low HDL-C/high HDL-P, c P<0.05 between high HDL-C/low 
HDL-P, d P<0.05 between high HDL-C/high HDL-P, * P<0.05 between all other groups.  
Values are presented as mean (standard error). Unless otherwise noted, all other models were adjusted for age, race, and year seven 
BMI.
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Table 4.4. Cardiovascular disease risk factor outcomes for HDL discordant/concordant women in the CARDIA study at year seven 
exam 
 
  
Low HDL-C/ 
Low HDL-P  
N=731 (34.55%) 
Low HDL-C/ 
High HDL-P  
N=343 (16.21%) 
High HDL-C/ 
Low HDL-P 
N=327 (15.45%) 
High HDL-C/ 
High HDL-P 
N=715 (33.79%) 
p 
value 
Anthropometrics (not adjusted for BMI)         
BMI (kg/m2) 28.99 (0.24)c,d 28.80 (0.34)c,d  24.43 (0.36)a,b  25.03 (0.24)a,b <.0001 
Waist Circumference (cm) 84.64 (0.50)c,d 85.66 (0.72)c,d 73.74 (0.76)* 76.27 (0.51)* <.0001 
Cardiorespiratory Fitness 
(min) 
          
VO2max  8.35 (0.18) 8.21 (0.25) 8.72 (0.29) 8.89 (0.19) 0.0922 
Blood Pressure (mmHg)           
Systolic blood pressure 105.17 (0.42)d 105.70 (0.61) 103.96 (0.64)d 106.63 (0.43)a 0.0032 
Diastolic blood pressure 67.40 (0.35) 67.75 (0.51) 66.65 (0.53)d 68.36 (0.36)c 0.0426 
Carbohydrate Metabolism           
Glucose (mg/dL) 90.38 (0.63) 91.09 (0.90) 88.34 (0.95) 89.17 (0.64) 0.119 
Insulin (uU/mL) 13.75 (0.66)b 17.01 (0.95)* 13.23 (1.01)b 13.97 (0.67)b 0.0171 
Inflammatory Markers           
GlycA (µmol/L) 408.75 (2.25)b,c 423.68 (3.24)* 379.11 (3.41)*    407.78 (2.29)b,c <.0001 
C-Reactive Protein (ug/mL) 3.40 (0.34) 3.73 (0.49) 4.33 (0.52) 3.36 (0.35) 0.4027 
a P<0.05 between low HDL-C/low HDL-P, b P<0.05 between low HDL-C/high HDL-P, c P<0.05 between high HDL-C/low HDL-
P, d P<0.05 between high HDL-C/high HDL-P, * P<0.05 between all other groups.  
Values are presented as mean (standard error). Unless otherwise noted, all other models were adjusted for age, race, and year seven 
BMI.
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Table 4.5. Lipoprotein subclass outcomes for LDL discordant/concordant men in the CARDIA study at year seven exam 
 
  
Low LDL-C/ 
Low LDL-P  
N=752 (42.87%) 
Low LDL-C/ 
High LDL-P  
N=134 (7.64%) 
High LDL-C/ 
Low LDL-P 
N=125 (7.13%) 
High LDL-C/ 
High LDL-P 
N=743 (42.36%) 
p 
value 
Demographics            
Age 31.46 (0.13)b,d 32.41 (0.31)b 31.87 (0.32) 32.52 (0.13)a <.0001 
% White 50.66 56.72 60.8 57.74 0.0204 
Continuous LDL Discordance (Percentile difference between LDL-C and LDL-P)     
Continuous LDL Discordance 0.07 (0.42)b,c -24.59 (0.97)* 21.77 (1.01)* 0.57 (0.42)b,c <.0001 
Lipid Panel,  (mg/dL)         
Total Cholesterol 150.93 (0.87)* 169.70 (2.02)* 185.22 (2.10)* 208.15 (0.88)* <.0001 
Triglycerides 80.40 (2.01)b,d 130.38 (4.70)* 75.58 (4.87)b,d 103.37 (2.03)* <.0001 
HDL-C  50.40 (0.45)b,d 46.78 (1.05)a,c 50.54 (1.09)b,d 45.69 (0.46)a,c <.0001 
LDL-C 83.97 (0.71)* 96.27 (1.66)* 119.00 (1.73)* 141.26 (0.72)* <.0001 
Lipoprotein Particle Size (nm)           
HDL-P size  8.97 (0.01)b,d 8.82 (0.03)* 8.94 (0.03)b,d 8.74 (0.01)* <.0001 
LDL-P size 20.75 (0.02)* 20.39 (0.04)* 21.15 (0.04)* 20.84 (0.02)* <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)       
Total HDL-P  22.50 (0.11) 22.32 (0.26) 23.04 (0.27) 22.72 (0.11) 0.1242 
Small HDL-P  14.29 (0.11)* 14.96 (0.26)a,d 15.23 (0.27)a,d 16.00 (0.11)* <.0001 
Medium HDL-P 6.27 (0.08)b,d 5.72 (0.19)a 6.10 (0.20)d 5.35 (0.08)a,c <.0001 
Large HDL-P 1.94 (0.04)* 1.63 (0.09)a,d 1.71 (0.10)a,d 1.38 (0.04)* <.0001 
Total LDL-P 1088.81 (8.79)* 1483.59 (20.50)* 1265.45 (21.26)* 1766.90 (8.87)* <.0001 
Small LDL-P 669.31 (14.99)* 1093.50 (34.95)* 564.59 (36.26)* 979.32 (15.12)* <.0001 
Medium LDL-P 205.69 (11.51)c,d 216.94 (26.83)c,d 318.87 (27.84)* 472.45 (11.61)* <.0001 
Large LDL-P 213.81 (7.00)* 173.15 (16.33)* 381.99 (16.94)* 315.13 (7.07)* <.0001 
a P<0.05 between low LDL-C/low LDL-P, b P<0.05 between low LDL-C/high LDL-P, c P<0.05 between high LDL-C/low LDL-
P, d P<0.05 between high LDL-C/high LDL-P, * P<0.05 between all other groups 
Values are presented as mean (standard error).Continuous discordance and age were assessed via univariable regression analyses. 
Race percentage was assessed via chi-square. Unless otherwise noted, all other models were adjusted for age, race, and year seven 
BMI.
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Table 4.6. Lipoprotein subclass outcomes for LDL discordant/concordant women in the CARDIA study at year seven exam 
 
  
Low LDL-C/ 
Low LDL-P  
N=897 (42.53%) 
Low LDL-C/ 
High LDL-P  
N=172  (8.16%) 
High LDL-C/ 
Low LDL-P 
N=158 (7.49%) 
High LDL-C/ 
High LDL-P 
N=882 (41.82%) 
p 
value 
Demographics            
Age 31.87 (0.12) 31.94 (0.28) 32.35 (0.29) 32.19 (0.12) 0.185 
% White 54.52 44.77 58.86 45.12 <.0001 
Continuous LDL Discordance (Percentile difference between LDL-C and LDL-P)     
Continuous LDL Discordance 0.38 (0.45)b,c -26.94 (1.06)* 24.91 (1.06)* 0.70 (0.46)b,c <.0001 
Lipid Panel,  (mg/dL)         
Total Cholesterol 149.15 (0.71)* 164.88 (1.66)* 180.39 (1.67)* 200.27 (0.73)* <.0001 
Triglycerides 59.64 (1.31)b,d 84.16 (3.06)a,c 63.29 (3.07)b,d 81.92 (1.34)a,c <.0001 
HDL-C  57.27 (0.43)d 56.50 (1.00)d 55.53 (1.00) 53.78 (0.44)a,b <.0001 
LDL-C 79.44 (0.57)* 91.04 (1.32)* 111.67 (1.33)* 129.60 (0.58)* <.0001 
Lipoprotein Particle Size (nm)           
HDL-P size  9.28 (0.01)b,d 9.15 (0.03)* 9.25 (0.03)b,d 9.08 (0.01)* <.0001 
LDL-P size 20.88 (0.01)* 20.69 (0.03)* 21.31 (0.03)* 21.08 (0.01)* <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)       
Total HDL-P  21.69 (0.09)b,d 22.24 (0.22)a 21.67 (0.22)d 22.25 (0.10)a.c 0.0002 
Small HDL-P  12.06 (0.10)c,d 12.40 (0.22)d 12.85 (0.23)a,d 13.37 (0.10)* <.0001 
Medium HDL-P 6.79 (0.08)b,c 7.19 (0.19)* 6.28 (0.19)a,b 6.63 (0.08)b 0.0042 
Large HDL-P 2.85 (0.05)c,d 2.65 (0.11)d 2.53 (0.11)a,d 2.25 (0.05)* <.0001 
Total LDL-P 1058.04 (7.07)* 1455.07 (16.46)* 1207.26 (16.53)* 1660.40 (7.20)* <.0001 
Small LDL-P 612.92 (11.81)* 994.78 (27.49)* 478.78 (27.61)* 840.9 (12.03)* <.0001 
Medium LDL-P 182.27 (9.13) 195.83 (21.25) 276.12 (21.34) 385.31 (9.30) <.0001 
Large LDL-P 262.85 (6.63)c,d 264.45 (15.42)c,d 452.35 (15.48)a,b 434.19 (6.75)a,b <.0001 
a P<0.05 between low LDL-C/low LDL-P, b P<0.05 between low LDL-C/high LDL-P, c P<0.05 between high LDL-C/low 
LDL-P, d P<0.05 between high LDL-C/high LDL-P, * P<0.05 between all other groups 
Values are presented as mean (standard error).Continuous discordance and age were assessed via univariable regression analyses. 
Race percentage was assessed via chi-square. Unless otherwise noted, all other models were adjusted for age, race, and year seven 
BMI.
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Table 4.7. Cardiovascular disease risk factor outcomes for LDL discordant/concordant men in the CARDIA study at year seven exam 
 
  
Low LDL-C/ 
Low LDL-P  
N=752 (42.87%) 
Low LDL-C/ 
High LDL-P  
N=134 (7.64%) 
High LDL-C/ 
Low LDL-P 
N=125 (7.13%) 
High LDL-C/ 
High LDL-P 
N=743 (42.36%) 
p 
value 
Anthropometrics (not adjusted for BMI)         
BMI (kg/m2) 25.23 (0.17)b,d 28.17 (0.39)a,c 25.12 (0.41)b,d 27.64 (0.17)a,c <.0001 
Waist Circumference (cm) 84.69 (0.41)b,d 92.54 (0.96)a,c 84.14 (0.99)b,d 91.05 (0.41)a,c <.0001 
Cardiorespiratory Fitness (min) 
  
        
VO2max  11.72 (0.18) 11.46 (0.43) 11.55 (0.49) 11.39 (0.18) 0.6578 
Blood Pressure (mmHg)           
Systolic blood pressure 112.00 (0.41)d 113.76 (0.95) 111.64 (0.99) 113.60 (0.41)a 0.0236 
Diastolic blood pressure 70.59 (0.35)d 71.23 (0.82) 71.05 (0.85) 72.69 (0.35)a 0.0005 
Carbohydrate Metabolism           
Glucose (mg/dL) 93.00 (0.66)b,d 97.36 (1.54)a,c 92.36 (1.59)b,d 95.37 (0.67)a,c 0.0104 
Insulin (uU/mL) 14.55 (0.54) 15.95 (1.27) 13.26 (1.28) 13.91 (0.54) 0.3673 
Inflammatory Markers           
GlycA (µmol/L) 375.94 (2.21)* 396.54 (5.16)* 360.01 (5.35)* 384.18 (2.23)* <.0001 
C-Reactive Protein (ug/mL) 2.30 (0.16) 2.45 (0.37) 1.77 (0.39) 1.94 (0.16) 0.2462 
a P<0.05 between low LDL-C/low LDL-P, b P<0.05 between low LDL-C/high LDL-P, c P<0.05 between high LDL-C/low LDL-P, 
d P<0.05 between high LDL-C/high LDL-P, * P<0.05 between all other groups 
Values are presented as mean (standard error). Unless otherwise noted, all other models were adjusted for age, race, and year seven 
BMI.
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Table 4.8. Cardiovascular disease risk factor outcomes for LDL discordant/concordant women in the CARDIA study at year seven 
exam 
 
  
Low LDL-C/ 
Low LDL-P  
N=897 (42.53%) 
Low LDL-C/ 
High LDL-P  
N=172 (8.16%) 
High LDL-C/ 
Low LDL-P 
N=158 (7.49%) 
High LDL-C/ 
High LDL-P 
N=882 (41.82%) 
p 
value 
Anthropometrics (not adjusted for BMI)         
BMI (kg/m2) 25.43 (0.22)* 26.94 (0.52)a,d 27.50 (0.52)a 28.34 (0.22)a,d <.0001 
Waist Circumference (cm) 76.87 (0.46)* 80.92 (1.10)a,d 80.88 (1.10)a,d 83.65 (0.47)* <.0001 
Cardiorespiratory Fitness (min) 
  
        
VO2max  8.84 (0.17) 8.24 (0.38) 8.69 (0.36) 8.31 (0.16) 0.1174 
Blood Pressure (mmHg)           
Systolic blood pressure 105.13 (0.38) 106.09 (0.88) 104.82 (0.88) 105.98 (0.38) 0.3258 
Diastolic blood pressure 66.80 (0.32)d 67.57 (0.73) 67.07 (0.74) 68.62 (0.32)a 0.0009 
Carbohydrate Metabolism           
Glucose (mmol/L) 88.50 (0.55)d 90.87 (1.27) 88.81 (1.27) 90.78 (0.56)a 0.0212 
Insulin (pmol/L) 13.72 (0.59) 16.09 (1.41) 12.97 (1.39) 14.63 (0.60) 0.2969 
Inflammatory Markers           
GlycA (µmol/L) 395.7 (2.03)b,d 422.53 (4.73)a,c 393.01 (4.75)b,d 416.46 (2.07)a,c <.0001 
C-Reactive Protein (mg/dL) 3.71 (0.31) 3.97 (0.71) 2.08 (0.72) 3.64 (0.31) 0.18 
a P<0.05 between low LDL-C/low LDL-P, b P<0.05 between low LDL-C/high LDL-P, c P<0.05 between high LDL-C/low LDL-P, 
d P<0.05 between high LDL-C/high LDL-P, * P<0.05 between all other groups 
Values are presented as mean (standard error). Unless otherwise noted, all other models were adjusted for age, race, and year seven 
BMI.
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Table 4.9. Correlations of CVD Risk Factors with Baseline Continuous HDL 
Discordance  
 
  
Continuous HDL 
Discordance 
Correlation 
p 
Value 
Lipid panel,  (mg/dL)     
Total Cholesterol -0.15 <.0001 
Triglycerides -0.28 <.0001 
HDL-C  0.35 <.0001 
LDL-C -0.19 <.0001 
Lipoprotein Particle Size (nm)     
HDL-P size  0.66 <.0001 
LDL-P size 0.31 <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L) 
Total HDL-P  -0.47 <.0001 
Small HDL-P  -0.73 <.0001 
Medium HDL-P 0.09 <.0001 
Large HDL-P 0.47 <.0001 
Total LDL-P -0.23 <.0001 
Small LDL-P -0.29 <.0001 
Medium LDL-P -0.06 0.0003 
Large LDL-P 0.25 <.0001 
Anthropometrics (not adjusted for year 7 BMI)   
BMI (kg/m2) -0.27 <.0001 
Waist Circumference (cm) -0.33 <.0001 
Cardiorespiratory Fitness (min)     
VO2max  0.08 0.0063 
Blood Pressure (mmHg)     
Systolic Blood Pressure -0.09 <.0001 
Diastolic Blood Pressure -0.11 <.0001 
Carbohydrate Metabolism     
Glucose (mg/dL) -0.12 <.0001 
Insulin (uU/mL) -0.06 0.0001 
Inflammatory Markers     
GlycA (µmol/L) -0.23 <.0001 
C-Reactive Protein (ug/mL) 0.02 0.2714 
All models adjusted for year 7 age, race, sex, and BMI (except  
anthropometrics).
 
 56 
Table 4.10. Correlations of CVD Risk Factors with Baseline Continuous  
LDL Discordance 
 
  
Continuous LDL 
Discordance 
Correlation 
p 
Value 
Lipid panel,  (mg/dL)     
Total Cholesterol 0.18 <.0001 
Triglycerides -0.28 <.0001 
HDL-C  0.04 0.022 
LDL-C 0.27 <.0001 
Lipoprotein Particle Size (nm)     
HDL-P size  0.13 <.0001 
LDL-P size 0.51 <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L) 
Total HDL-P  0.00 0.8342 
Small HDL-P  0.03 0.045 
Medium HDL-P -0.05 0.0023 
Large HDL-P 0.02 0.1586 
Total LDL-P -0.24 <.0001 
Small LDL-P -0.50 <.0001 
Medium LDL-P 0.13 <.0001 
Large LDL-P 0.36 <.0001 
Anthropometrics (not adjusted for year 7 BMI)   
BMI (kg/m2) -0.06 0.0007 
Waist Circumference (cm) -0.09 <.0001 
Cardiorespiratory Fitness (min)     
VO2max  0.05 0.0637 
Blood Pressure (mmHg)     
Systolic Blood Pressure -0.07 <.0001 
Diastolic Blood Pressure -0.02 0.2468 
Carbohydrate Metabolism     
Glucose (mg/dL) -0.07 <.0001 
Insulin (uU/mL) -0.09 <.0001 
Inflammatory Markers     
GlycA (µmol/L) -0.18 <.0001 
C-Reactive Protein (ug/mL) -0.04 0.0131 
All models adjusted for year 7 age, race, sex, and BMI (except  
anthropometrics).
 
 57 
 
Figure 4.1. HDL Discordance Based Risk of Type 2 Diabetes in Males (a) and Females 
(b) Male models were adjusted for race and time varying age, BMI, and smoking. Female 
models additionally adjusted for time varying gestational diabetes, and parity 
 
 
Figure 4.2. LDL Discordance Based Risk of Type 2 Diabetes in Males (a) and Females 
(b). Male models were adjusted for race and time varying age, BMI, and smoking. 
Female models additionally adjusted for time varying gestational diabetes, and parity 
 
a b
a b
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Figure 4.3. HDL Discordance Based Risk of Metabolic Syndrome in Males (a) and 
Females (b). Male models were adjusted for race and time varying age, BMI, and 
smoking. Female models additionally adjusted for time varying gestational diabetes, and 
parity. 
  
 
Figure 4.4. LDL Discordance Based Risk of Metabolic Syndrome in Males (a) and 
Females (b). Male models were adjusted for race and time varying age, BMI, and 
smoking. Female models additionally adjusted for time varying gestational diabetes, and 
parity.
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CHAPTER 5 
DISCORDANCE BETWEEN LIPOPROTEIN CHOLESTEROL AND PARTICLE 
CONCENTRATIONS AND EXERCISE INDUCED CHANGES IN CARDIOVASCULAR 
DISEASE RISK FACTORS 
Abstract 
Purpose: To examine the association between lipoprotein discordance status and exercise 
induced changes in lipoprotein discordance, as well as multiple cardiovascular disease risk 
factors among participants from two previously completed exercise interventions. 
Methods: The HERITAGE Family Study (N=715) was a progressive 20-week 
standardized endurance training intervention. The HART-D study (N=214) was a nine-
month exercise intervention in type 2 diabetics with a control group and three training 
groups: 1) Aerobic training only (AT), 2) Resistance training only (RT), 3) Combined 
AT/RT. Four exclusive HDL and LDL discordance groups were created based on baseline 
median lipoprotein cholesterol/particle concentrations as follows: 1) low/low (< median 
for both cholesterol and particle), 2) low/high (< median cholesterol, ≥ median particle), 3) 
high/low, and 4) high/high. Continuous discordance levels were created at baseline and 
post intervention by subtracting individual particle percentile ranking from cholesterol 
percentile ranking (e.g. HDL-C – HDL-P). The association between sex-specific median 
based (HERITAGE) and continuous (HART-D) lipoprotein discordance and exercise 
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training induced changes in multiple CVD risk factors was assessed via multivariable linear 
regression. 
Results: In HERITAGE women, low HDL-P groups (Low/Low and High/Low) 
experienced mean increases in continuous HDL discordance with exercise training, while 
high HDL-P groups (Low/High and High/High) experienced decreases (p<0.05 for all). 
Only discordant HDL groups in men experienced significant continuous HDL discordance 
changes, with the Low/High group experiencing a mean decrease and the High/Low group 
increasing (p<0.0001 for both).  In both men and women, the two LDL discordant groups 
were the only to change continuous LDL discordance, with the High/Low group 
experiencing a mean decrease and the Low/High group increasing (p<0.01 for all). In 
HART-D, baseline continuous HDL discordance was significantly associated (p<0.05) 
with changes in continuous HDL discordance (β=-0.273), mean HDL-P size (β=0.003), 
and concentrations of triglycerides (β=0.515), total HDL-P (β=0.016), large HDL-P 
(β=0.007), and small HDL-P (β=-2.163) Baseline continuous LDL discordance was 
significantly associated (p<0.05) with changes in continuous LDL discordance (β=-0.495), 
LDL-C (β=-0.266), and body fat percentage (β=-0.014).  
Conclusions: Lipoprotein discordance status is primarily associated with exercise training 
induced changes in lipoprotein subclass measures. In general, exercise training decreased 
LDL discordance but did not improve continuous HDL discordance. Our study shows that 
lipoprotein discordance is minimally predictive of exercise training responses outside of 
lipoprotein subclass measures. 
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1. Introduction 
Limitations in our ability to predict cardiovascular disease (CVD) risk have led to 
increased clinical interest in identifying novel risk markers and refining the measurement 
of traditional risk factors, such as the cholesterol content of  low-density (LDL-C) and 
high-density (HDL-C) lipoproteins.56 Both LDL and HDL are largely heterogeneous 
lipoproteins, varying in size, density, composition and function and thus may not be solely 
represented by their cholesterol content. Advanced techniques such as nuclear magnetic 
resonance (NMR) are able to provide subclass measurements of these lipoproteins, 
revealing their diversity and offering alternative measures in estimating CVD risk. 
One popular alternative to cholesterol content is measuring the concentration of 
both LDL and HDL particles (LDL-P and HDL-P respectively). Both total LDL-P and 
HDL-P often outperform their respective cholesterol contents in CVD risk estimation.14-16 
However, these analyses use cholesterol content and particle concentration separately in 
their statistical models, thus treating them as independent predictors of CVD risk. As LDL-
C and HDL-C are not biologically independent of their particle concentrations, treating 
them a as independent predictors fails to account for both the biological similarities and 
differences represented by each variable.29 
Lipoprotein discordance, a ratio between cholesterol content and particle 
concentration (e.g. LDL-C/LDL-P), accounts for both the biological similarities and 
differences represented by each variable. This ratio represents the relative similarity 
between an individual’s cholesterol and particle concentration measures by ranking them 
by their cholesterol levels and particle concentrations separately within their respective 
study cohort. Studies examining the association of LDL discordance (LDL-C/LDL-P) on 
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cardiovascular risk15, 17-23 have found that in concordant groups, both LDL-C and LDL-P 
equally predict risk. However, in discordant LDL-C/LDL-P (e.g., high LDL-C/low LDL-
P), risk of adverse cardiovascular events is positively associated with LDL-P.18, 19 
Regarding HDL discordance, higher levels of HDL discordance (higher HDL-P and lower 
HDL-C) have been associated with decreased CVD risk.17 This relationship, however, may 
be confounded by disease status such as diabetes or metabolic syndrome.17 
Exercise is well known to improve the lipoprotein profile and individual lipoprotein 
subclasses, including increases in HDL-C and large HDL-P concentrations, along with 
decreases in small LDL-P concentration and increases in LDL-P size.24, 25 However, no 
studies have examined the effects of regular exercise on LDL and HDL discordance. 
Furthermore, the association between baseline discordance status and exercise induced 
changes in CVD risk factors has yet to be explored. Therefore, the purpose of this study is 
to assess the effects of regular exercise on LDL and HDL discordance, as well as examine 
the association of baseline discordance status on exercise induced changes in multiple CVD 
risk factors. 
2. Methods 
Data from two completed studies, spanning four distinct training programs, were 
used for the present analyses. Details of each individual study are given below.  
2.1. HERITAGE Family Study 
Full details of the design and methods of the HERITAGE Family Study (hereafter 
HERITAGE) have been previously reported.37 Briefly, HERITAGE included 715 black 
(34%), and white men and women (55%) aged 17-65 years. Participants were sedentary at 
baseline with a BMI less than 40 kg/m2 and normotensive to mildly hypertensive (<160/100 
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mmHg). Each participant completed a 20-week exercise intervention which consisted of 
three exercise sessions per week on a cycle ergometer. Exercise sessions started at 30 
minutes at the heart rate associated with 55% of maximal oxygen consumption (VO2max) 
for the first two weeks and progressed to a target of 50 minutes at 75% of VO2max for each 
session, which was maintained for the final six weeks of training.37  
2.2. HART-D Study 
The design, recruitment, and methods of HART-D have been previously described 
.57 The HART-D study included 214 sedentary (54.7% White, 40.6% Black, 3.7% Asian, 
0.5% Hispanic, 0.5% Other) men and women (63.6%) aged 30 – 75 years with type 2 
diabetes and HbA1c levels of 6.5% to 11.0%. Participants had a BMI less than 48 kg/m2, 
blood pressure below 160/100 mmHg, fasting triglycerides below 500 mg/dL, urine protein 
less than 100 mg/dL and serum creatinine under 1.5 mg/dL. Further exclusion criteria 
included use of an insulin pump, history of stroke, advanced neuropathy or retinopathy, or 
any serious medical condition that prevented participants from adhering to the protocol or 
exercising safely. 
HART-D was a nine-month exercise intervention with a control group and three 
exercise training groups: aerobic exercise training only (AT), resistance exercise training 
only (RT), and a combination of aerobic and resistance training (AT/RT). The non-exercise 
control group was asked to maintain their normal level of activity during the 9 months and 
were offered weekly stretching and relaxation classes. 
The AT group exercised three to five days/week at an intensity of 50–80% of their 
VO2max for a total dose of 12 kcal/kg/week. Caloric expenditure was adjusted weekly based 
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upon weight changes. American College of Sports Medicine equations were used to 
calculate caloric expenditure and therefore time required per exercise session. 
The RT group trained 3 days/week. Each session included two sets of four upper 
body exercises (chest press, lateral pull-down, military press, and seated row), three sets of 
three lower body exercises (leg press, leg ex- tension, and hamstring curl), and two core 
exercises (abdominal crunches and back extensions). Each set consisted of 10-12 
repetitions. The prescribed weight was increased when participants could complete 12 
repetitions on the last set of each exercise for two consecutive sessions. 
The AT/RT group was prescribed 3 days/week of aerobic exercise at a dose of 10 
kcal/kg/week and 2 resistance training sessions per week. Resistance exercises and their 
progression were the same as those in the resistance training only group, however, only 
one set of each exercise was performed.  
2.3. Blood Samples 
Blood samples were collected from an antecubital vein into vacutainer tubes 
containing EDTA. Samples were taken in the morning after a 10 (HART-D) or 12 
(HERITAGE) hour fast. Samples for HERIATAGE were taken twice at baseline and 24 
and 72 hours after the last exercise training session. Samples for the HART-D study were 
collected within 48 to 96 hours of the final exercise bout.  
2.4. Lipids and Lipoproteins 
In HERITAGE plasma very low-density lipoproteins (VLDL) were isolated via 
ultracentrifugation. HDL fractions were obtained after precipitation of LDL in the 
infranatant by the heparin-manganese chloride method. Total cholesterol and triglyceride 
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levels were determined in plasma and lipoproteins via enzymatic methods (Technicon RA- 
500 Analyzer; Bayer Corporation Inc., Tarrytown, NY). 
For HART-D, fasting blood lipids (total cholesterol, LDL-C, HDL-C, and 
triglycerides) were analyzed on a DXC 600 Pro Clinical Chemistry Analyzer (Beckman 
Coulter Inc, Brea, California). 
2.5. Lipoprotein Subclass Profiles and GlycA 
Comprehensive lipoprotein profiling and GlycA analysis were performed on 
baseline and post-training plasma samples via NMR spectroscopy at Labcorp, Inc. 
(Morrisville, NC) using either the LipoProfile-3 (HERITAGE) or LipoProfile-4 (HART-
D) algorithm.36 Each measurement provides information on lipoprotein particle 
concentrations, including total, large, medium, and small HDL-P and LDL-P 
concentrations and mean HDL-P and LDL-P size. NMR signal amplitudes originating from 
the N-acetyl methyl group protons of N-acetylglucosamine residues on the glycan branches 
of glycoproteins were used to quantify GlycA concentrations. 
2.6 Defining HDL/LDL Discordance/Concordance Groups 
Baseline HDL and LDL based lipoprotein discordance for both studies were 
classified via two methods: 1) Median based discordance and 2) Continuous discordance. 
Post-intervention discordance was also classified via continuous discordance. 
For median based discordance, separate categorical discordant/concordant groups were 
made for LDL and HDL by denoting LDL-C, LDL-P, HDL-C, and HDL-P values greater 
than or equal to the sex-specific median value as high and below the median as low. Four 
exclusive cholesterol/particle concordant/discordant groups were made for both LDL and 
HDL from these base categories: 1) Low/Low (Concordantly low: below the median for 
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both cholesterol content and particle concentration), 2) Low/High (Discordant: below the 
median for cholesterol content, at or above the median for particle concentration), 3) 
High/Low (Discordant: at or above the median for cholesterol content, below the median 
for particle concentration), and 4) High/High (Concordantly high: at or above the median 
for both cholesterol content and particle concentration). Note that median based 
discordance/concordance groups as a whole will be referred to as discordance groups from 
here forward unless referencing a specific group. 
Lipoprotein cholesterol and particle concentrations were rank ordered into sex 
specific percentiles to establish continuous discordance status. Continuous discordance 
was then defined by subtracting an individual’s lipoprotein particle percentile from their 
lipoprotein cholesterol percentile. 
2.7. CVD risk factor measurements. 
Common CVD risk factor measurements for both HERITAGE and HART-D were 
BMI, body fat percentage, VO2max, resting blood pressure, fasting glucose, fasting insulin 
and CRP.37, 41, 47, 48, 57, 58 Risk factor measurements unique to HERITAGE were visceral 
adipose tissue, insulin sensitivity index, lipoprotein lipase and hepatic lipase.37, 40, 59 
HART-D analyses uniquely measured waist circumference and hemoglobin A1C.57, 60 
Methodology for CVD risk factor measurements can be found in supplemental methods. 
2.8. Statistical Analysis 
The association of baseline median based (HERITAGE) or continuous (HART-D) 
LDL and HDL discordance status with exercise induced changes in CVD risk factors was 
assessed via multivariable linear regression. HERITAGE models were stratified by sex and 
adjusted for age, race, baseline BMI, and baseline trait (i.e. adjusting for baseline HDL-C 
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when assessing for changes in HDL-C). HART-D models were adjusted for age, race, sex, 
baseline BMI, cholesterol medication, and baseline trait. HART-D models were 
additionally adjusted for training group assignment (Control group not included) with the 
interaction between discordance and intervention group assignment also being explored.  
3. Results 
3.1. HERITAGE  
HDL Discordance 
Median cutoffs for baseline HDL-C and total HDL-P were 35.57 mg/dl and 28.60 
µmol/L respectively in men and 42.72 mg/dl and 29.40 µmol/L respectively in women. 
Approximately 34% and 33% of men and women respectively, were concordantly low for 
HDL (Low HDL-C/Low HDL-P) while 35% of men and 34% of women were concordantly 
high. Thus about 31% of men and 33% of women had discordant levels of HDL-C and 
HDL-P (Table 5.1 and 5.2). 
In both male and female HDL discordance groups at baseline, more favorable risk 
factor profiles were primarily found in the two groups that had high HDL-C (High HDL-
C/Low HDL-P and High HDL-C/High HDL-P), regardless of discordance status. Both 
High HDL-C groups had the largest mean LDL-P size and concentration of large HDL-P 
(Tables 5.1 and 5.2).  
In males, High HDL-C groups displayed the lowest BMI (25.39 and 26.38 kg/m2 
respectively for High/Low and High/High vs 28.06 and 28.62 respectively for Low/Low 
and Low/High groups) and visceral adipose tissue (84.78 and 85.87 cm2 respectively for 
High/Low and High/High vs 106.05 and 113.86 for Low/Low and Low/High groups). The 
concordantly high group had significantly higher insulin sensitivity than all groups. The 
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Low/High HDL discordant group had the highest triglycerides and small LDL-P 
concentrations of all groups (Tables 5.1 and 5.3). 
In females, high HDL-C groups displayed the lowest BMI, percent body fat, and 
visceral adiposity as well. The High/Low discordant group had significantly lower 
triglycerides and small LDL-P concentration than all other groups. The Low/High 
discordant group had the highest visceral abdominal fat, and triglycerides, small LDL-P, 
and fasting glucose concentrations (Tables 5.2 and 5.4).  
Regarding exercise induced changes in risk factors, male HDL discordance groups 
displayed significant trends for changes in continuous HDL discordance, mean HDL-P size 
and total HDL-P and large HDL-P concentrations. Low HDL-P groups (Low/Low and 
High/Low) experienced mean increases in continuous HDL discordance while high HDL-
P groups (Low/High and High/High) experienced mean decreases with exercise training.  
On average, both High HDL-C groups increased HDL-P size, as well as total and large 
HDL-P concentrations, while the two Low HDL-C groups exhibited mean decreases in 
each of these outcomes (Tables 5.5 and 5.7).  
Similar to men, female HDL discordance groups displayed a trend for exercise 
induced changes continuous HDL discordance with Low HDL-P groups experiencing 
mean increases in continuous HDL discordance while high HDL-P groups experienced 
mean decreases with exercise training. The Low/High HDL discordant group showed 
significantly different changes in HDL-P size, LDL-P size, and small LDL-P concentration 
relative to all other groups, with the direction of change opposite of that compared to all 
three other groups for each of these traits. Specifically, this group was the only group to 
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decrease HDL-P or LDL-P size and increase small LDL-P concentration with training 
(Tables 5.6 and 5.8). 
LDL Discordance 
Median cutoffs for baseline LDL-C and total LDL-P were 113.08 mg/dl and 
1048.50 nmol/L respectively in men and 109.21 mg/dl and 889.00 nmol/L respectively in 
women. Approximately 41% of both men and women were concordantly low for LDL 
(Low LDL-C/Low LDL-P) while 43% of men and 41% of women were concordantly high. 
Thus, about 16% of men and 18% of women had discordant levels of LDL-C and LDL-P 
(Table 5.9 and 5.10). 
In both male and female LDL discordance groups, more favorable risk factor 
profiles were found in the two groups with the lowest LDL-P concentrations (Low LDL-
C/Low LDL-P and High LDL-C/Low LDL-P), regardless of LDL-C/discordance status 
(Tables 5.9 to 5.12). Both low LDL-P groups had the lowest BMI and triglycerides and 
small LDL-P concentrations. The concordantly low groups displayed the lowest total 
cholesterol, LDL-C, and total LDL-P concentrations of all groups. The concordantly High 
groups displayed the highest total cholesterol, LDL-C, and LDL-P concentrations of all 
groups. Furthermore, the High/High concordant groups in both sexes had the smallest mean 
HDL-P size (Tables 5.9 and 5.10), while in females the concordantly high group had the 
lowest insulin sensitivity (Table 5.12). In males, Low LDL-P groups displayed the lowest 
percent body fat (Tables 5.11).  
Regarding exercise induced changes in risk factors, male LDL discordance groups 
displayed significant trends for differential changes in continuous LDL discordance as well 
as total and large LDL-P concentrations (Tables 5.13 and 5.14). In males, both low LDL-
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P groups (Low LDL-C/Low LDL-P and High LDL-C/Low LDL-P) experienced mean 
decreases in continuous LDL discordance while high LDL-P groups experienced increases. 
Both high LDL-C groups increased total LDL-P concentration, as opposed to decreased 
concentrations in low LDL-C groups. The Low/Low concordant group was the only group 
to display an overall mean decrease in Large LDL-P (Table 5.13). In female LDL 
discordance groups, significant associations were found for continuous LDL discordance 
triglycerides and small and large LDL-P concentrations (Table 5.14). The High/Low LDL 
discordant group was the only to experience a mean decrease in continuous LDL 
discordance. The High/High concordant group was the only group to have a mean increase 
in triglycerides, while the Low/Low concordant group was the only to decrease small LDL-
P with training. All groups except the Low/High discordant group increased large LDL-P 
concentration (Table 5.14). 
3.2. HART-D Study 
Median cutoffs for baseline HDL-C and total HDL-P were 47.60 mg/dl and 22.00 
µmol/L respectively. Median cutoffs for baseline for LDL-C and total LDL-P were 93.50 
mg/dl and 1060.50 nmol/L respectively (Tables 5.17 and 5.19). 
Median based HDL discordance groups with High HDL-C displayed favorable risk 
factor profiles with the highest mean HDL-P size, medium and large HDL-P 
concentrations, and the lowest small LDL-P concentrations (Table 5.17). Median based 
LDL discordance groups with Low LDL-P displayed favorable risk factor profiles with the 
lowest small LDL-P concentrations (Table 5.19)  
Significant associations of baseline continuous HDL discordance were found with 
exercise induced changes in continuous HDL discordance, triglycerides, mean HDL-P size, 
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and total and large HDL-P and small LDL-P concentrations (Table 5.21). No significant 
interactions between HDL discordance and group were found. Significant associations of 
continuous LDL discordance were found with exercise induced changes in continuous LDL 
discordance, LDL-C concentration, and body fat (Table 5.22). A significant interaction 
between continuous LDL discordance and group was found for systolic blood pressure 
although none of the groups displayed a significant change in this outcome. 
4. Discussion 
Our study found multiple cross-sectional differences in CVD risk factor profiles 
between lipoprotein discordance groups among relatively healthy (HERITAGE) and type 
2 diabetic (HART-D) adults. In both studies, risk factor profiles tended to follow HDL-C 
levels regardless of HDL discordance status, with the higher HDL-C groups displaying 
more favorable profiles. The Low HDL-C/High HDL-P discordant group displayed the 
worst baseline risk factor profile through all studies, displaying the highest concentrations 
of triglycerides, small HDL-P and small LDL-P, all of which have been positively 
associated with CVD risk.61, 62 Furthermore, HERITAGE females in the Low HDL-C/High 
HDL-P group increased atherogenic small LDL-P concentrations with exercise training, 
while all other groups experienced presumed beneficial decreases in small LDL-P. With 
the limited literature on HDL discordance, our study sheds light on the association between 
HDL discordance and multiple CVD risk factors in both healthy and diabetic adults.  
In LDL discordance groups, risk factor profiles tended to track with LDL-P 
concentration, with low LDL-P groups displaying more favorable profiles. These findings 
are consistent with prior literature showing that risk factor profiles and risk of adverse CVD 
related outcomes is lower in those with low LDL-P concentrations.15, 17-23   
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Knowing the individual associations of lipoprotein measures, as well as the 
association of lipoprotein discordance, with CVD outcomes and risk factors it is valuable 
to examine whether exercise reduces/corrects lipoprotein discordance and whether 
discordance results in differential changes to individual lipoprotein and risk factor 
measures. In both studies, main effects of HDL discordance were primarily seen in HDL 
metrics such as HDL-P size and large HDL-P concentration. Specifically, those with High 
HDL-C tended to have more favorable changes in these metrics with training. In males 
from HERITAGE, the Low HDL-C groups had the lowest large HDL-P concentrations at 
baseline and showed a mean decrease in large HDL-P with training, while both High HDL-
C groups showed mean increases. Overall, in HERITAGE exercise training resulted in 
decreased continuous HDL discordance in High HDL-P groups and increased discordance 
in Low HDL-P groups. Increases in discordance would indicate a higher post-training 
percentile for HDL-C, a lower post-training percentile for HDL-P or a combination of both. 
Decreases in discordance would essentially mean opposite responses (relative to increases) 
in post training lipoprotein percentiles. As continuous discordance is based on an 
individual’s ranks of lipoprotein metrics (cholesterol or particle concentration) within the 
study cohort, using continuous discordance changes may be misleading as all participants 
may have seen some level of change that inherently affects the rankings of all individuals 
within the study. Thus, changes in individual lipoprotein subfractions may be more 
informative. 
Similarly, in the HART-D study, a higher baseline continuous HDL discordance 
(more HDL-C than HDL-P) was associated with increased large HDL-P concentration with 
exercise training. Thus, those with higher concentrations of large HDL-P and/or larger 
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mean HDL-P size tended to further increase these values with training, whereas those with 
lower concentrations of large HDL-P or smaller mean HDL-P size tended to decrease these 
values with training. Basleine HDL discordance was also negatively associated with 
changes in continuous HDL discordance. Interestingly, continuous HDL discordance was 
also negatively associated with training induced changes in triglycerides and small LDL-
P. Therefore, beneficial training induced changes were associated with higher baseline 
HDL-C. 
Similar to the findings for HDL, the association of LDL discordance with training-
induced changes in risk factors was primarily seen for changes in LDL metrics such as 
LDL-C and large LDL-P. In both sexes in HERITAGE, those above the median for LDL-
C levels (High LDL-C) were the only individuals to significantly increase large LDL-P 
concentrations with training, regardless of LDL discordance status. In HART-D, higher 
continuous LDL discordance (higher LDL-C than LDL-P) was negatively associated with 
changes continuous LDL discordance and LDL-C. Both results suggest potential 
regression to the mean. LDL discordance was not significantly associated with LDL-P in 
HART-D. 
While minimal effects were seen regarding median based discordance and exercise 
induced changes in non-lipoprotein CVD risk factors in HERITAGE, significant within 
group changes were observed in both studies. Within HERITAGE, all participants on 
average improved cardiorespiratory fitness regardless of HDL and LDL discordance status. 
Furthermore, all HDL discordance groups significantly decreased body fat percentage, 
while three of four LDL discordance groups in both males and females displayed similar 
changes. Within the HART-D study, all exercise groups significantly increased the 
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concentration of medium LDL-P, while the combined AT/RT group significantly reduced 
HbA1C levels.57 Thus, while discordance status may affect the lipoprotein profile and its 
ability to beneficially respond to regular exercise, individuals will still benefit from 
exercise regardless of discordance status across a number of clinically relevant phenotypes. 
Our study is the first to investigate the relationship between lipoprotein discordance 
with exercise induced changes in CVD risk factors, however, multiple studies have 
examined the effects of exercise training on lipoprotein subclass profiles. 24, 63-72 The most 
common findings in the literature are a decrease in small LDL-P concentration, 24, 63, 65, 67, 
71, 72 as well as increases in either large HDL-P or mean HDL-P size.24, 63, 65, 66, 68, 69  
Sarzynski et al24 showed that in HERITAGE  and five other exercise training studies there 
was an overall mean decrease in small LDL-P and increase in large HDL-P concentrations. 
In our HERITAGE analysis, these changes were isolated to certain discordance groups, 
with some even displaying opposite direction of effects. Thus, lipoprotein discordance may 
affect the common beneficial lipoprotein subclass changes associated with exercise 
training.  
4.1. Strengths and Limitations 
Our analysis is strengthened by the fact that we examined data from two large, well 
supervised and standardized exercise training studies. Furthermore, adherence in both 
studies was very high (>95% in HERITAGE, >70% in HART-D). NMR measures for both 
studies were standardized and performed in the same laboratory, thus minimizing 
measurement error. 
Our study is limited by the fact that HERITAGE did not include a control group. 
Thus, risk factor changes could only be assessed relative to baseline levels and changes 
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between groups. Analyses were also performed without post hoc correction. Thus, our 
results should be interpreted with caution as multiple phenotypes were tested.  
4.2. Conclusions 
Our analyses found that individuals with High HDL-C and Low LDL-P had more 
favorable baseline risk factor profiles, regardless of median based lipoprotein discordance 
status. The association of lipoprotein discordance with exercise induced changes in these 
risk factors was primarily limited to the specific lipoprotein metrics represented by each 
analysis (i.e. HDL subclass measures in HDL discordance analysis) while continuous HDL 
discordance was also negatively associated with training induced changes in triglycerides 
and small LDL-P concentration. In median based discordance analyses, individuals with 
High HDL-P decreased in mean continuous discordance (decreased HDL-C/increased 
HDL-P percentiles) while Low HDL-P individuals had opposing responses. Furthermore, 
while all but one female LDL discordant group (High LDL-C/Low LDL-P) increased mean 
continuous discordance (increased LDL-C/decreased LDL-P percentiles), males with Low 
LDL-P decreased in continuous discordance. Conversely, Men with High LDL-P increased 
continuous LDL discordance. In continuous discordance analysis, baseline lipoprotein 
discordance (both LDL and HDL) were negatively associated with training induced 
changes in continuous discordance. Thus, median based and continuous lipoprotein 
discordance may differentially associate with training induced changes in CVD risk 
factors. Nevertheless, all exercise training resulted in some level of beneficial risk factor 
change. Thus, while lipoprotein discordance may predict differential training induced 
lipoprotein subclass changes, individuals will still benefit from exercise across multiple 
clinically relevant risk factors.
 
 
Table 5.1. Baseline Lipoprotein subclass outcomes for HDL discordant/concordant men in the HERITAGE Family Study 
 
  
Low HDL-C/ 
Low HDL-P  
N=109 
(33.9%) 
Low HDL-C/ 
High HDL-P  
N=51 
(15.8%) 
High HDL-C/ 
Low HDL-P 
N=50 
(15.5%) 
High HDL-C/ 
High HDL-P 
N=112 
(34.8%) 
p 
value 
Demographics        
 
  
% White 78.90 66.67 56.00 75.00 0.0173 
Continuous HDL Discordance (% difference between HDL-C and 
HDL-P) 
  
 
  
Continuous HDL Discordance 1.62 (1.74)b,c -44.95 (2.54)* 40.59 (2.57)* 0.76 (1.72)b,c <.0001 
Cholesterol Measurements,  (mg/dL) 
  
    
 
  
Total Cholesterol 167.01 (3.35)b,d 179.03 (4.69)a 172.5 (4.72) 178.89 (3.23)a 0.0342 
Triglycerides 119.58 (6.3)b,c 208.4 (8.82)* 96.64 (8.88)a,b 108.56 (6.08)b <.0001 
HDL-C  30.82 (0.69)c,d 32.19 (0.97)c,d 40.5 (0.98)* 44.31 (0.67)* <.0001 
LDL-C 117.93 (2.95) 109.38 (4.13) 118.46 (4.16) 118.76 (2.85) 0.2556 
Lipoprotein Particle Size (nm)       
 
  
HDL-P size  8.71 (0.04)* 8.99 (0.05)a,c 9.16 (0.05)a,b 9.06 (0.03)a <.0001 
LDL-P size 20.57 (0.05)* 20.19 (0.07)* 21.09 (0.07)a,b 20.95 (0.05)a,b <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L) 
  
  
 
  
HDL-P  24.88 (0.29)* 31.72 (0.41)a,c 26.88 (0.41)* 32.37 (0.28)a,c <.0001 
Small HDL-P  16.58 (0.35)b,c 18.62 (0.49)* 14.59 (0.49)* 16.57 (0.34)b,c <.0001 
Medium HDL-P 5.93 (0.34)* 9.89 (0.47)* 7.96 (0.47)* 11.23 (0.32)* <.0001 
Large HDL-P 2.38 (0.14)* 3.21 (0.20)* 4.34 (0.20)a,b 4.56 (0.14)a,b <.0001 
LDL-P 1100.01 (27.67)c,d 1049.25 (38.74) 951.87 (39.01)a 1017.74 (26.71)a 0.0134 
Small LDL-P 670.96 (24.40)* 780.24 (34.16)* 444.18 (34.40)a,b 506.21 (23.55)a,b <.0001 
Large LDL-P 298.79 (16.58)b,d 140.2 (23.22)* 349.72 (23.38)b 349.55 (16.00)b <.0001 
a p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low 
HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). Demographics were assessed via chi-square. Continuous discordance was  
assessed via assessed via univariable regression analyses. Unless otherwise noted, all other models were adjusted for age, race,  
and baseline body mass index. 
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Table 5.2. Baseline Lipoprotein subclass outcomes for HDL discordant/concordant women in the HERITAGE Family Study 
 
  
Low HDL-C/ 
Low HDL-P  
N=131 (33.3%) 
Low HDL-C/ 
High HDL-P  
N=63 (16.0%) 
High HDL-C/ 
Low HDL-P 
N=66 (16.8%) 
High HDL-C/ 
High HDL-P 
N=133 (33.8%) 
p 
value 
Demographics            
% White 50.38 73.02 54.55 66.92 0.0047 
Continuous HDL Discordance (% difference between HDL-C and HDL-P) 
  
  
  
Continuous HDL Discordance -1.07 (1.56)b,c -39.54 (2.24)* 42.65 (2.19)* -1.36 (1.54)b,c <.0001 
Cholesterol Measurements,  (mg/dL)         
Total Cholesterol 155.76 (2.47)b,d 175.27 (3.71)a,c 158.32 (3.45)b,d 176.26 (2.47)a,c <.0001 
Triglycerides 90.88 (3.61)b,c 131.35 (5.41)* 66.95 (5.03)* 90.26 (3.60)b,c <.0001 
HDL-C  35.71 (0.54)* 37.9 (0.81)* 49.67 (0.75)* 52.65 (0.54)* <.0001 
LDL-C 107.89 (2.29)b 118.69 (3.43)a,c 101.4 (3.19)b,d 113.06 (2.28)c 0.002 
Lipoprotein Particle Size 
(nm) 
          
HDL-P size  9.07 (0.03)c,d 9.06 (0.04)c,d 9.80 (0.04)* 9.51 (0.03)* <.0001 
LDL-P size 20.89 (0.04)c,d 20.74 (0.07)c,d 21.25 (0.06)a,b 21.21 (0.04)a,b <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L) 
  
  
  
Total HDL-P  25.73 (0.28)b,d 32.42 (0.42)* 26.51 (0.39)b,d 34.93 (0.28)* <.0001 
Small HDL-P  13.87 (0.37)b,c 16.29 (0.56)* 10.78 (0.52)* 13.93 (0.37)b,c <.0001 
Medium HDL-P 7.98 (0.38)b,d 11.79 (0.56)* 8.46 (0.52)b,d 13.69 (0.37)* <.0001 
Large HDL-P 3.88 (0.16)c,d 4.34 (0.24)c,d 7.27 (0.22)a,b 7.31 (0.16)a,b <.0001 
Total LDL-P 927.14 (22.81)b,c 1122.52 (34.21)* 743.42 (31.83)* 905.7 (22.79)b,c <.0001 
Small LDL-P 480.47 (16.86)* 636.32 (25.28)* 267.34 (23.52)* 371.51 (16.84)* <.0001 
Large LDL-P 317.55 (15.08)d 326.27 (22.62)d 354.16 (21.04) 382.96 (15.07)a,b 0.017 
a p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low HDL-
P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). Demographics were assessed via chi-square. Continuous discordance was assessed via 
assessed via univariable regression analyses. Unless otherwise noted, all other models were adjusted for age, 
race, and baseline body mass index.
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Table 5.3. Baseline cardiovascular disease risk factor outcomes for HDL discordant/concordant men in the  
HERITAGE Family Study 
 
  
Low HDL-C/ 
Low HDL-P  
N=109 
(33.9%) 
Low HDL-C/ 
High HDL-P  
N=51 
(15.8%) 
High HDL-C/ 
Low HDL-P 
N=50 
(15.5%) 
High HDL-C/ 
High HDL-P 
N=112 
(34.8%) 
p 
value 
Anthropometrics (Baseline measurements not adjusted for baseline BMI)     
BMI (kg/m2) 28.06 (0.47)c,d 28.62 (0.66)c,d 25.39 (0.67)a,b 26.38 (0.46)a,b 0.0004 
Body Fat (%) 24.10 (0.79)c 25.91 (1.11)c,d 21.11 (1.09)a,b 22.29 (0.77)b 0.0063 
Visceral abdominal  Fat (cm2) 106.05 (4.88)c,d 113.86 (6.81)c,d 84.78 (6.87)a,b 85.87 (4.73)a,b 0.0003 
Cardiorespiratory Fitness (ml/kg/min)         
VO2max  34.96 (0.48) 34.72 (0.68) 34.58 (0.69) 35.27 (0.47) 0.822 
Blood Pressure (mmHg)           
Systolic blood pressure 121.45 (1.05) 124.32 (1.49) 122.92 (1.49) 121.86 (1.02) 0.3872 
Diastolic blood pressure 69.45 (0.78) 72.81 (1.11) 71.40 (1.10) 70.68 (0.76) 0.0699 
Carbohydrate/Lipid Metabolism           
Glucose (mmol/L) 5.32 (0.06) 5.25 (0.08) 5.18 (0.08) 5.19 (0.06) 0.2979 
Insulin (pmol/L) 77.24 (4.85) 84.21 (6.94) 70.90 (6.80) 65.29 (4.66) 0.0884 
Insulin Sensitivity (μU/min/mL) 3.03 (0.24)d 2.77 (0.34)d 3.07 (0.34)d 3.94 (0.23)* 0.0058 
Hepatic Lipase (nmol/mL/min) 217.40 (6.16) 225.80 (8.97) 204.24 (8.97) 209.91 (5.95) 0.3027 
Lipoprotein Lipase (nmol/mL/min) 52.88 (2.70)c,d 44.85 (3.94)c,d 63.91 (3.94)a,b 66.17 (2.61)a,b <.0001 
Inflammatory Markers           
GlycA (µmol/L) 307.85 (4.71) 324.89 (6.60) 301.16 (6.65) 313.94 (4.55) 0.0624 
C-Reactive Protein (mg/dL) 0.21 (0.02) 0.15 (0.03) 0.17 (0.03) 0.20 (0.02) 0.2912 
a p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-
C/low HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). Unless otherwise noted, all models were adjusted for age, race, and  
baseline body mass index.
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Table 5.4. Baseline cardiovascular disease risk factor outcomes for HDL discordant/concordant Women in the HERITAGE  
Family Study 
 
  
Low HDL-C/ 
Low HDL-P  
N=131 
(33.3%) 
Low HDL-C/ 
High HDL-P  
N=63 
(16.0%) 
High HDL-C/ 
Low HDL-P 
N=66 
(16.8%) 
High HDL-C/ 
High HDL-P 
N=133 
(33.8%) 
p 
value 
Anthropometrics (Baseline measurements not adjusted for baseline BMI)     
BMI (kg/m2) 27.15 (0.42)* 29.19 (0.62)* 24.61 (0.59)a,b 25.39 (0.43)a,b <.0001 
Body Fat (%) 34.80 (0.73)c,d 36.41 (1.11)c,d 29.29 (1.01)a,b 30.76 (0.74)a,b <.0001 
Visceral abdominal  Fat (cm2) 79.34 (3.08)* 101.89 (4.47)* 55.58 (4.21)a,b 61.99 (3.03)a,b  <.0001 
Cardiorespiratory Fitness (ml/kg/min)         
VO2max  26.47 (0.36)d 27.1 (0.54) 27.15 (0.5) 27.91 (0.35)a 0.0484 
Blood Pressure (mmHg)           
Systolic blood pressure 117.61 (0.96) 118.77 (1.43) 114.65 (1.35) 118.86 (0.95) 0.0767 
Diastolic blood pressure 68.67 (0.64) 67.89 (0.95) 66.62 (0.89) 68.52 (0.63) 0.2448 
Carbohydrate/Lipid Metabolism           
Glucose (mmol/L) 5.03 (0.05)b,d 5.25 (0.07)* 4.91 (0.07)b 4.83 (0.05)a,b <.0001 
Insulin (pmol/L) 73.58 (3.84)c 83.06 (5.80)c,d 60.57 (5.37)a,b 65.59 (3.85)b 0.0178 
Insulin Sensitivity (μU/min/mL) 3.36 (0.25)c,d 3.24 (0.36)c,d 4.41 (0.34)a,b 4.4 (0.25)a,b 0.0029 
Hepatic Lipase (nmol/mL/min) 171.59 (5.06)c,d 165.69 (7.42)c,d 134.75 
(7.06)a,b 
135.33 (5.07)a,b <.0001 
Lipoprotein Lipase (nmol/mL/min) 54.8 (2.72)c,d 50.69 (3.99)c,d 86.18 (3.79)a,b 80.05 (2.72)a,b <.0001 
Inflammatory Markers           
GlycA (µmol/L) 327.21 (4.34)* 361.61 (6.51)a,c 308.26 (6.06)* 348.99 (4.36)a,c <.0001 
C-Reactive Protein (mg/dL) 0.26 (0.05)d 0.42 (0.08) 0.25 (0.08)d 0.47 (0.05)a,c 0.0144 
a p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low 
HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). Unless otherwise noted, all models were adjusted for age, race, and baseline body mass 
index.  
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Table 5.5. Delta Lipoprotein subclass outcomes for HDL discordant/concordant men in the HERITAGE Family Study 
 
  
Low HDL-C/ 
Low HDL-P  
N=109 
(33.9%) 
Low HDL-C/ 
High HDL-P  
N=51 
(15.8%) 
High HDL-C/ 
Low HDL-P 
N=50 
(15.5%) 
High HDL-C/ 
High HDL-P 
N=112 
(34.8%) 
p 
value 
Continuous HDL Discordance (Percentile difference between HDL-C and HDL-P)   
Continuous HDL Discordance 3.20 (2.41)b,c -19.49 (3.48)* 17.89 (3.55)* -2.38 (2.33)b,c <.0001 
Cholesterol Measurements,  (mg/dL)         
Total Cholesterol -1.92 (1.65)d -2.78 (2.24)d 2.74 (2.29) 2.91 (1.54)a,b 0.0491 
Triglycerides -7.75 (4.24) -9.74 (6.38) -1.06 (6.04) -3.25 (4.06) 0.6911 
HDL-C  1.27 (0.45) 1.02 (0.57) 1.14 (0.58) 1.25 (0.45) 0.9819 
LDL-C -2.21 (1.46) -0.50 (2.01) 1.81 (2.04) 1.11 (1.37) 0.2622 
Lipoprotein Particle Size (nm)           
HDL-P size  -0.06 (0.03)c,d -0.1 (0.03)c,d 0.09 (0.04)a,b 0.04 (0.02)a,b 0.0001 
LDL-P size -0.05 (0.04)c,d -0.1 (0.06)c,d 0.12 (0.06)a,b 0.13 (0.04)a,b 0.0044 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)       
HDL-P  -1.09 (0.37)c,d -1.13 (0.44)c,d 0.29 (0.43)a,b 0.71 (0.34)a,b 0.0001 
Small HDL-P  0.17 (0.32) 0.44 (0.46) -0.86 (0.47) -0.10 (0.31) 0.2324 
Medium HDL-P -1.61 (0.40)c,d -0.83 (0.50)d 0.13 (0.50)a 0.74 (0.36)a,b 0.0002 
Large HDL-P -0.17 (0.12)c,d -0.39 (0.16)c,d 0.57 (0.16)a,b 0.42 (0.12)a,b <.0001 
LDL-P -22.65 (15.68) 23.47 (21.82) 20.81 (22.15) -2.63 (15.06) 0.221 
Small LDL-P -18.70 (16.60) 16.49 (23.90) -24.92 (23.90) -47.38 (16.26) 0.1793 
Large LDL-P 13.57 (13.04) 11.54 (19.41) 49.83 (18.55) 36.38 (12.84) 0.3104 
ap<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-
C/low HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). All models were adjusted for age, race,  baseline body mass index and   
baseline trait (i.e. delta HDL-C adjusted for baseline HDL-C).
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Table 5.6. Delta Lipoprotein subclass outcomes for HDL discordant/concordant Women in the HERITAGE Family Study 
 
  
Low HDL-C/ 
Low HDL-P  
N=131 
(33.3%) 
Low HDL-C/ 
High HDL-P  
N=63 
(16.0%) 
High HDL-C/ 
Low HDL-P 
N=66 
(16.8%) 
High HDL-C/ 
High HDL-P 
N=133 
(33.8%) 
p 
value 
Continuous HDL Discordance (% difference between HDL-C and HDL-P)     
Continuous HDL Discordance 4.35 (2.21)* -19.98 (3.12)* 21.5 (3.04)* -5.26 (2.14)* <.0001 
Cholesterol Measurements,  (mg/dL)         
Total Cholesterol 1.51 (1.5) 3.27 (2.14) 2.60 (2.00) 2.71 (1.44) 0.9072 
Triglycerides -1.84 (2.71) 3.64 (4.15) 1.09 (3.83) -2.58 (2.63) 0.5265 
HDL-C  1.54 (0.61) 0.84 (0.75) 3.01 (0.70) 1.74 (0.60) 0.2256 
LDL-C 0.16 (1.26) 1.63 (1.86) -0.53 (1.74) 1.21 (1.23) 0.8013 
Lipoprotein Particle Size (nm)           
HDL-P size  0.03 (0.02)b -0.07 (0.03)* 0.08 (0.04)b 0.04 (0.02)b 0.0303 
LDL-P size 0.01 (0.04)b -0.17 (0.06)* 0.12 (0.05)b 0.03 (0.04)b 0.0027 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)     
HDL-P  -0.94 (0.40)c,d -0.59 (0.48)d 0.56 (0.48)a 0.65 (0.41)a,b 0.006 
Small HDL-P  -0.30 (0.33) 0.5 (0.51) -0.51 (0.48) -0.28 (0.33) 0.5166 
Medium HDL-P -1.21 (0.38)d -0.15 (0.54) -0.93 (0.51)d 0.98 (0.38)a,c 0.0019 
Large HDL-P 0.21 (0.14)c -0.1 (0.19)c,d 0.74 (0.18)a,b 0.38 (0.14)b 0.0265 
LDL-P -6.42 (15.15) 39.62 (23.65) -9.54 (22.01) 22.17 (15.15) 0.2921 
Small LDL-P -11.7 (15.04)b 78.95 (24.06)* -62.76 (22.17)b,d -7.25 (15.2)b,c 0.001 
Large LDL-P 14.46 (11.09) 7.52 (16.56) 34.36 (15.4) 39.59 (11.11) 0.2569 
a p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-
C/low HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). All models were adjusted for age, race,  baseline body mass index and   
baseline trait (i.e. delta HDL-C adjusted for baseline HDL-C). 
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Table 5.7. Delta cardiovascular disease risk factor outcomes for HDL discordant/concordant men in the HERITAGE  
Family Study 
 
  
Low HDL-C/ 
Low HDL-P  
N=109 
(33.9%) 
Low HDL-C/ 
High HDL-P  
N=51 
(15.8%) 
High HDL-C/ 
Low HDL-P 
N=50 
(15.5%) 
High HDL-C/ 
High HDL-P 
N=112 
(34.8%) 
p 
value 
Anthropometrics           
BMI (kg/m2) -0.22 (0.08) -0.31 (0.11) -0.1 (0.11) -0.11 (0.07) 0.4006 
Body Fat (%) -1.08 (0.19) -0.68 (0.26) -1.12 (0.25) -0.8 (0.18) 0.4297 
Visceral abdominal  Fat (cm2) -10.08 (1.71) -6.96 (2.31) -9.12 (2.37) -7.12 (1.63) 0.512 
Cardiorespiratory Fitness (ml/kg/min)         
VO2max  5.06 (0.3) 4.60 (0.41) 5.35 (0.42) 5.72 (0.28) 0.1057 
Blood Pressure (mmHg)           
Systolic blood pressure -1.50 (0.69) -0.20 (0.95) 0.44 (0.95) -1.06 (0.64) 0.3326 
Diastolic blood pressure -0.90 (0.57)c,d -1.38 (0.79)c,d 1.28 (0.79)a,b 0.87 (0.54)a,b 0.0122 
Carbohydrate/Lipid Metabolism           
Glucose (mmol/L) 0.11 (0.04)b -0.05 (0.06)a,d -0.02 (0.06) 0.11 (0.04)b 0.0423 
Insulin (pmol/L) -6.77 (2.49) -7.78 (3.45) -13.18 (3.56) -7.10 (2.35) 0.4751 
Insulin Sensitivity (μU/min/mL) 0.49 (0.24) 0.36 (0.33) -0.07 (0.34) 0.28 (0.22) 0.5815 
Hepatic Lipase (nmol/mL/min) -6.06 (4.53)c,d -18.04 (6.41)c -37.02 (6.53)a,b -22.35 (4.34)a 0.0008 
Lipoprotein Lipase (nmol/mL/min) 7.82 (2.34) 5.32 (3.35) 17.07 (3.38) 11.89 (2.3) 0.0632 
Inflammatory Markers           
GlycA (µmol/L) -8.47 (3.5) -4.70 (4.92) 0.18 (4.95) -7.95 (3.37) 0.4741 
C'-Reactive Protein (mg/dL) 0.06 (0.02)d 0.07 (0.03)d 0.04 (0.03) -0.02 (0.02)a,b 0.0436 
a p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low 
HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). All models were adjusted for age, race,  baseline body mass index and   
baseline trait (i.e. delta GlycA adjusted for baseline GlycA
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Table 5.8. Delta cardiovascular disease risk factor outcomes for HDL discordant/concordant women in the HERITAGE  
Family Study 
 
  
Low HDL-C/ 
Low HDL-P  
N=131 
(33.3%) 
Low HDL-C/ 
High HDL-P  
N=63 
(16.0%) 
High HDL-C/ 
Low HDL-P 
N=66 
(16.8%) 
High HDL-C/ 
High HDL-P 
N=133 
(33.8%) 
p 
value 
Anthropometrics           
BMI (kg/m2) -0.13 (0.08) -0.08 (0.12) -0.03 (0.11) -0.09 (0.08) 0.9322 
Body Fat (%) -0.68 (0.2) -0.71 (0.29) -0.74 (0.26) -0.75 (0.19) 0.9943 
Visceral abdominal  Fat (cm2) -2.39 (1.2) -2.59 (1.77) -4.71 (1.62) -5.02 (1.15) 0.3767 
Cardiorespiratory Fitness (ml/kg/min)         
VO2max  4.92 (0.25) 4.95 (0.36) 5.49 (0.33) 4.96 (0.24) 0.5356 
Blood Pressure (mmHg)           
Systolic blood pressure 0.54 (0.61) -1.47 (0.9) 0.38 (0.84) -0.1 (0.6) 0.3078 
Diastolic blood pressure 0.32 (0.49) 0.51 (0.72) 0.62 (0.67) 0.56 (0.48) 0.9803 
Carbohydrate/Lipid Metabolism           
Glucose (mmol/L) 0.15 (0.04) 0.18 (0.06) 0.08 (0.06) 0.02 (0.04) 0.0674 
Insulin (pmol/L) -3.94 (2.25)c -3.25 (3.33)c -13.02 (3.1)a,b -9.67 (2.23) 0.0492 
Insulin Sensitivity (μU/min/mL) 0.17 (0.21) -0.17 (0.3) -0.04 (0.29) 0.11 (0.21) 0.7759 
Hepatic Lipase (nmol/mL/min) -8.12 (3.67) -0.39 (5.32) -13.9 (4.96) -10.17 (3.67) 0.3211 
Lipoprotein Lipase (nmol/mL/min) 2.73 (2.39)c,d -3.64 (3.48)c,d 12.32 (3.25)a,b 11.09 (2.36)a,b 0.0017 
Inflammatory Markers           
GlycA (µmol/L) -6.22 (3.33) -0.72 (5.06) -6.00 (4.74) 1.30 (3.36) 0.4241 
C-Reactive Protein (mg/dL) -0.07 (0.04)b 0.17 (0.06)* -0.10 (0.06)b 0.00 (0.04)b 0.0035 
a p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low 
HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). All models were adjusted for age, race,  baseline body mass index and   
baseline trait (i.e. delta GlycA adjusted for baseline GlycA).
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Table 5.9. Baseline Lipoprotein subclass outcomes for LDL discordant/concordant men in the HERITAGE Family Study 
 
  
Low LDL-C/ 
Low LDL-P  
N=133 
(41.3%) 
Low LDL-C/ 
High LDL-P  
N=28 
(8.7%) 
High LDL-C/ 
Low LDL-P 
N=23 
(7.1%) 
High LDL-C/ 
High LDL-P 
N=138 
(42.9%) 
p 
value  
Demographics            
% White 71.43 60.87 67.86 75.36 0.4845 
Continuous LDL Discordance (% difference between LDL-C and LDL-P)     
Continuous LDL Discordance 0.11 (1.06)b,c -25.26 (2.56)* 22.31 (2.32)* -0.43 (1.04)b,c <.0001 
Cholesterol Measurements,  (mg/dL)         
Total Cholesterol 144.72 (2.30)* 169.55 (4.93)a,d 181.95 (4.44)a,d 202.53 (2.26)* <.0001 
Triglycerides 111.83 (6.76)b,d 149.39 (14.50)a,c 100.17 (13.07)b,d 142.87 (6.66)a,c 0.0013 
HDL-C  37.43 (0.87) 40.60 (1.87)d 40.29 (1.68)d 36.1 (0.86)b,c 0.0356 
LDL-C 89.92 (1.79)* 103.3 (3.85)* 127.1 (3.47)* 144.15 (1.77)* <.0001 
Lipoprotein Particle Size (nm)           
HDL-P size  9.07 (0.04)d 9.02 (0.08)d 9.07 (0.07)d 8.81 (0.04)* <.0001 
LDL-P size 20.74 (0.06)b,c 20.48 (0.12)a,b 21.16 (0.11)* 20.66 (0.05)c <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)     
HDL-P  29.07 (0.43)b 31.31 (0.91)* 28.68 (0.82)b 28.42 (0.42)b 0.032 
Small HDL-P  16.04 (0.35) 17.54 (0.74) 15.87 (0.67) 17.04 (0.34) 0.0936 
Medium HDL-P 9.05 (0.39) 9.85 (0.83) 8.8 (0.75) 8.27 (0.38) 0.2487 
Large HDL-P 3.97 (0.16)d 3.93 (0.35)d 4.00 (0.31)d 3.11 (0.16)* 0.0007 
LDL-P 774.18 (17.14)* 1110.03 (36.75)* 957.63 (33.12)* 1302.19 (16.87)* <.0001 
Small LDL-P 451.88 (22.39)b,d 698.27 (47.99)a,c 424.14 (43.25)b,d 749.1 (22.03)a,c <.0001 
Large LDL-P 222.71 (16.21)c,d 280.74 (34.75)d 369.13 (31.32)a 362.30 (15.95)a,b <.0001 
a p<0.05 between low LDL-C/low LDL-P, b p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-C/low 
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). Demographics were assessed via chi-square. Continuous discordance was  
assessed via assessed via univariable regression analyses. Unless otherwise noted, all other models were adjusted for age, 
race, and baseline body mass index
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Table 5.10. Baseline Lipoprotein subclass outcomes for LDL discordant/concordant women in the HERITAGE Family Study 
 
  
Low LDL-C/ 
Low LDL-P  
N=160 
(40.7%) 
Low LDL-C/ 
High LDL-P  
N=35 
(8.9%) 
High LDL-C/ 
Low LDL-P 
N=36 
(9.1%) 
High LDL-C/ 
High LDL-P 
N=162 
(41.2%) 
p 
value  
Demographics            
% White 60.63 42.86 50.00 66.05 0.0404 
Continuous LDL Discordance (% difference between LDL-C and LDL-P)     
Continuous LDL Discordance 0.27 (0.97)b,c -26.76 (2.08)* 26.83 (2.05)* -0.47 (0.97)b,c <.0001 
Cholesterol Measurements,  (mg/dL)         
Total Cholesterol 141.35 (1.67)* 153.71 (3.37)* 180.49 (3.34)* 190.66 (1.69)* <.0001 
Triglycerides 75.80 (3.41)b,d 120.63 (6.88)a,c 75.36 (6.81)b,d 107.10 (3.45)a,c <.0001 
HDL-C  45.72 (0.76)* 37.95 (1.54)* 50.1 (1.53)* 42.58 (0.77)* <.0001 
LDL-C 86.20 (1.35)* 99.60 (2.73)* 121.62 (2.71)* 134.34 (1.37)* <.0001 
Lipoprotein Particle Size (nm)         
HDL-P size  9.48 (0.03)* 9.03 (0.06)* 9.72 (0.06)* 9.18 (0.03)* <.0001 
LDL-P size 20.94 (0.04)* 20.65 (0.08)* 21.57 (0.08)* 21.1 (0.04)* <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)     
HDL-P  29.37 (0.41) 30.08 (0.83) 29.16 (0.83) 30.69 (0.42) 0.1264 
Small HDL-P  13.38 (0.36)b,c 15.13 (0.72)a,c 11.17 (0.72)* 14.33 (0.36)c 0.0002 
Medium HDL-P 9.78 (0.40) 10.59 (0.81) 10.48 (0.80) 11.34 (0.40) 0.0728 
Large HDL-P 6.21 (0.18)* 4.35 (0.37)a,c 7.52 (0.37)* 5.03 (0.19)a,c <.0001 
LDL-P 674 (14.80)* 1004.55 (29.87)* 804.2 (29.57)* 1173.41 (14.97)* <.0001 
Small LDL-P 338.09 (15.52)* 571.40 (31.32)a,c 219.28 (31.01)* 542.04 (15.70)a,c <.0001 
Large LDL-P 235.67 (11.99)* 315.92 (24.21)* 415.97 (23.97)a,b 452.61 (12.14)a,b <.0001 
a p<0.05 between low LDL-C/low LDL-P, b p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-C/low 
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). Demographics were assessed via chi-square. Continuous discordance was  
assessed via assessed via univariable regression analyses. Unless otherwise noted, all other models were adjusted for age, race, 
and baseline body mass index.
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Table 5.11. Baseline cardiovascular disease risk factor outcomes for LDL discordant/concordant men in the HERITAGE Family 
Study 
 
  
Low LDL-C/ 
Low LDL-P  
N=133 
(41.3%) 
Low LDL-C/ 
High LDL-P  
N=28 
(8.7%) 
High LDL-C/ 
Low LDL-P 
N=23 
(7.1%) 
High LDL-C/ 
High LDL-P 
N=138 
(42.9%) 
p 
value  
Anthropometrics (Baseline measurements not adjusted for baseline BMI)     
BMI (kg/m2) 25.08 (0.43)b,d 29.35 (0.93)* 26.32 (0.85)b,d 28.82 (0.42)a,c <.0001 
Body Fat (%) 19.66 (0.70)b,d 27.21 (1.61)* 21.90 (1.36)b,d 26.23 (0.67)a,c <.0001 
Visceral abdominal  Fat (cm2) 82.61 (4.55)b,d 108.15 (9.92)a 89.55 (9.02)d 109.90 (4.48)a,c 0.0002 
Cardiorespiratory Fitness (ml/kg/min)         
VO2max  36.18 (0.46)d 34.41 (0.98) 34.87 (0.86) 33.89 (0.45)a 0.0069 
Blood Pressure (mmHg)           
Systolic blood pressure 123.68 (1) 119.9 (2.15) 119.64 (1.93) 122.04 (0.99) 0.1661 
Diastolic blood pressure 71.48 (0.75) 68.78 (1.61) 69.06 (1.45) 70.85 (0.74) 0.2726 
Carbohydrate/Lipid Metabolism         
Glucose (mmol/L) 5.26 (0.06) 5.22 (0.12) 5.13 (0.11) 5.24 (0.05) 0.735 
Insulin (pmol/L) 75.87 (4.73) 71.97 (10) 65.31 (8.8) 72.31 (4.63) 0.7542 
Insulin Sensitivity (μU/min/mL) 3.38 (0.24) 2.57 (0.5) 3.20 (0.47) 3.40 (0.23) 0.4613 
Hepatic Lipase (nmol/mL/min) 222.31 (5.88) 190.31 (12.74) 204.56 (11.5) 211.52 (5.85) 0.1049 
Lipoprotein Lipase (nmol/mL/min) 56.74 (2.68) 64.10 (5.81) 68.52 (5.24) 56.40 (2.66) 0.1157 
Inflammatory Markers           
GlycA (µmol/L) 302.00 (4.40)b,d 348.11 (9.44)* 303.00 (8.51)b 316.03 (4.33)a,b 0.0002 
C-Reactive Protein (mg/dL) 0.18 (0.02) 0.25 (0.04) 0.13 (0.04) 0.19 (0.02) 0.2665 
a p<0.05 between low LDL-C/low LDL-P, b p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-
C/low LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). Unless otherwise noted, all models were adjusted for age, race, and baseline  
body mass index. 
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Table 5.12. Baseline cardiovascular disease outcomes for LDL discordant/concordant Women in the HERITAGE  
Family Study 
 
  
Low LDL-C/ 
Low LDL-P  
N=160 
(40.7%) 
Low LDL-C/ 
High LDL-P  
N=35 
(8.9%) 
High LDL-C/ 
Low LDL-P 
N=36 
(9.1%) 
High LDL-C/ 
High LDL-P 
N=162 
(41.2%) 
p 
value  
Anthropometrics (Baseline measurements not adjusted for baseline BMI)     
BMI (kg/m2) 25.16 (0.40)b,d 27.20 (0.81)a,c 24.59 (0.80)b,d 27.99 (0.40)a,c <.0001 
Body Fat (%) 30.95 (0.70)d 33.32 (1.46) 29.58 (1.44)d 35.09 (0.70)a,c <.0001 
Visceral abdominal  Fat (cm2) 61.77 (2.98)b,d 75.79 (5.96)a,c 57.49 (5.89)b,d 86.76 (2.94)a,c <.0001 
Cardiorespiratory Fitness (ml/kg/min)         
VO2max  27.09 (0.33) 27.9 (0.66) 28.27 (0.67) 26.8 (0.34) 0.1595 
Blood Pressure (mmHg)           
Systolic blood pressure 117.19 (0.89) 118.59 (1.80) 113.75 (1.83) 118.94 (0.90) 0.0721 
Diastolic blood pressure 67.32 (0.59) 68.34 (1.19) 68.40 (1.21) 68.92 (0.6) 0.3316 
Carbohydrate/Lipid Metabolism           
Glucose (mmol/L) 4.95 (0.05) 5.14 (0.09) 4.93 (0.09) 4.97 (0.05) 0.2842 
Fasting insulin (pmol/L) 72.33 (3.62) 69.19 (7.4) 59.69 (7.22) 70.33 (3.69) 0.4837 
Insulin Sensitivity (μU/min/mL) 4.32 (0.23)d 4.88 (0.46)d 4.13 (0.44)d 3.08 (0.23)* 0.0002 
Hepatic Lipase (nmol/mL/min) 157.68 (4.84)d 167.05 (9.68)d 160.16 (9.72) 140.75 (4.97)a,b 0.0267 
Lipoprotein Lipase (nmol/mL/min) 66.48 (2.76) 55.93 (5.51)c,d 77.06 (5.53)b 70.34 (2.83)b 0.0404 
Inflammatory Markers           
GlycA (µmol/L) 324.08 (4.14)b,d 350.82 (8.35)a,c 317.31 (8.27)b,d 350.07 (4.21)a,c <.0001 
C-Reactive Protein (mg/dL) 0.28 (0.05)b 0.61 (0.10)* 0.26 (0.10)b 0.39 (0.05)b 0.0162 
a p<0.05 between low LDL-C/low LDL-P, b p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-C/low 
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). Unless otherwise noted, all models were adjusted for age, race, and baseline  
body mass index.  
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Table 5.13. Delta Lipoprotein subclass outcomes for LDL discordant/concordant men in the HERITAGE Family Study 
 
  
Low LDL-C/ 
Low LDL-P  
N=133 
(41.3%) 
Low LDL-C/ 
High LDL-P  
N=28 
(8.7%) 
High LDL-C/ 
Low LDL-P 
N=23 
(7.1%) 
High LDL-C/ 
High LDL-P 
N=138 
(42.9%) 
p 
value 
Continuous LDL Discordance (Percentile difference between LDL-C and LDL-P)     
Continuous LDL Discordance -0.8 (1.15)b,c 15.07 (2.8)* -10 (2.49)* 0.04 (1.14)b,c <.0001 
Cholesterol Measurements,  (mg/dL)         
Total Cholesterol -0.62 (1.92) 2.48 (3.34) 3.38 (2.96) 0.49 (1.85) 0.6318 
Triglycerides -4.65 (3.98) -15.92 (8.49) 8.78 (7.55) -7.15 (3.9) 0.1623 
HDL-C  1.39 (0.38) 1.27 (0.82) 0.24 (0.72) 1.19 (0.37) 0.5503 
LDL-C -2.47 (1.8) 2.91 (3.01) 1.54 (2.64) 1.44 (1.76) 0.3272 
Lipoprotein Particle Size (nm)           
HDL-P size  0.04 (0.02) -0.02 (0.05) 0 (0.05) -0.06 (0.02) 0.082 
LDL-P size -0.03 (0.04) 0.07 (0.09) 0.11 (0.08) 0.06 (0.04) 0.2648 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)     
HDL-P  -0.3 (0.29) -0.82 (0.62) -0.21 (0.56) -0.04 (0.28) 0.6867 
Small HDL-P  -0.36 (0.31) -0.1 (0.66) -0.2 (0.6) 0.27 (0.3) 0.5597 
Medium HDL-P -0.24 (0.35) -0.77 (0.74) -0.5 (0.67) -0.28 (0.34) 0.9142 
Large HDL-P 0.19 (0.11) 0.31 (0.24) 0.31 (0.21) -0.05 (0.11) 0.2274 
LDL-P -24.83 (19.48)c -71.96 (31.63)c,d 45.08 (28.65)a,b 27.31 (19.02)b 0.0087 
Small LDL-P -28.26 (16.73) -80.65 (33.73) -30.96 (31.03) -6.03 (16.39) 0.2164 
Large LDL-P -15.12 (12.43)c,d 35.51 (25.94) 79.14 (23.6)a 58.1 (12.27)a 0.0002 
a p<0.05 between low LDL-C/low LDL-P, b p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-C/low 
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). All models were adjusted for age, race,  baseline body mass index and   
baseline trait (i.e. delta HDL-C adjusted for baseline HDL-C). 
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Table 5.14. Delta Lipoprotein subclass outcomes for LDL discordant/concordant women in the HERITAGE Family Study 
 
  
Low LDL-C/ 
Low LDL-P  
N=160 
(40.7%) 
Low LDL-C/ 
High LDL-P  
N=35 
(8.9%) 
High LDL-C/ 
Low LDL-P 
N=36 
(9.1%) 
High LDL-C/ 
High LDL-P 
N=162 
(41.2%) 
p 
value 
Continuous LDL Discordance (Percentile difference between LDL-C and LDL-P)     
Continuous LDL Discordance  0.32 (1.24)b,c 7.02 (2.63)* -11.48 (2.59)* 0.70 (1.21)b,c <.0001 
Cholesterol Measurements,  (mg/dL)         
Total Cholesterol 2.88 (1.71) 2.17 (2.74) -1.36 (2.70) 2.88 (1.62) 0.5261 
Triglycerides -3.79 (2.58)d -3.42 (5.02) -9.79 (4.95)d 4.96 (2.48)a,c 0.0218 
HDL-C  2.2 (0.45) 0.87 (0.91) 1.92 (0.9) 1.51 (0.44) 0.5547 
LDL-C 0.51 (1.59) 0.52 (2.38) -1.36 (2.34) 1.23 (1.52) 0.8093 
Lipoprotein Particle Size (nm)           
HDL-P size  0.04 (0.02) -0.01 (0.04) 0.05 (0.04) 0.01 (0.02) 0.6284 
LDL-P size 0.03 (0.03) -0.14 (0.07) 0.09 (0.07) 0 (0.03) 0.1264 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)       
HDL-P  0.16 (0.29) -0.33 (0.59) 0.19 (0.59) -0.33 (0.3) 0.6464 
Small HDL-P  -0.23 (0.31) 0.14 (0.63) -0.47 (0.63) -0.21 (0.32) 0.9255 
Medium HDL-P -0.27 (0.34) -0.19 (0.69) -0.77 (0.68) -0.10 (0.34) 0.8588 
Large HDL-P 0.30 (0.11) 0.15 (0.23) 0.59 (0.23) 0.30 (0.12) 0.5934 
LDL-P -12.44 (18.63) 2.41 (28.77) 44.74 (28.84) 24.36 (18.6) 0.3127 
Small LDL-P -44.88 (14.72)b,d 45.20 (28.89)a 1.20 (29.69) 21.05 (14.93)a 0.009 
Large LDL-P 9.05 (11.27)d -17.60 (20.66)c,d 47.89 (20.63)b 46.94 (11.30)a,b 0.0232 
a p<0.05 between low LDL-C/low LDL-P, b p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-C/low 
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). All models were adjusted for age, race,  baseline body mass index and   
baseline trait (i.e. delta HDL-C adjusted for baseline HDL-C). 
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Table 5.15. Delta cardiovascular disease outcomes for LDL discordant/concordant men in the HERITAGE Family Study 
 
  
Low LDL-C/ 
Low LDL-P  
N=133 
(41.3%) 
Low LDL-C/ 
High LDL-P  
N=28 
(8.7%) 
High LDL-C/ 
Low LDL-P 
N=23 
(7.1%) 
High LDL-C/ 
High LDL-P 
N=138 
(42.9%) 
p 
value 
Anthropometrics           
BMI (kg/m2) -0.24 (0.07) -0.19 (0.16) -0.14 (0.14) -0.12 (0.07) 0.684 
Body Fat (%) -1.13 (0.18) -0.72 (0.4) -1.09 (0.32) -0.71 (0.17) 0.3853 
Visceral abdominal  Fat (cm2) -8.13 (1.60) -7.40 (3.42) -6.43 (3.01) -9.19 (1.57) 0.8455 
Cardiorespiratory Fitness (ml/kg/min)         
VO2max  5.43 (0.28) 4.61 (0.60) 6.05 (0.52) 5.04 (0.29) 0.2349 
Blood Pressure (mmHg)           
Systolic blood pressure -0.62 (0.64) -0.01 (1.38) -0.52 (1.22) -1.13 (0.64) 0.8593 
Diastolic blood pressure 0.57 (0.54) 0.26 (1.15) 0.21 (1.04) -0.60 (0.54) 0.4895 
Carbohydrate/Lipid Metabolism           
Glucose (mmol/L) 0.01 (0.04) 0.11 (0.09) 0.16 (0.08) 0.09 (0.04) 0.2978 
Insulin (pmol/L) -7.94 (2.36) -6.65 (4.97) -6.58 (4.55) -9.10 (2.33) 0.9376 
Insulin Sensitivity (μU/min/mL) 0.49 (0.23) -0.05 (0.47) 0.90 (0.43) 0.07 (0.21) 0.2461 
Hepatic Lipase (nmol/mL/min) -18.57 (4.39) -13.32 (9.57) -24.43 (8.54) -19.60 (4.44) 0.8456 
Lipoprotein Lipase (nmol/mL/min) 10.97 (2.23) 15.14 (4.82) 5.96 (4.37) 9.84 (2.23) 0.5305 
Inflammatory Markers           
GlycA (µmol/L) -4.21 (3.36) -11.63 (7.31) -3.86 (6.46) -7.38 (3.29) 0.7911 
C-Reactive Protein (mg/dL) 0.03 (0.02) 0.03 (0.05) 0.05 (0.04) 0.03 (0.02) 0.9473 
a p<0.05 between low LDL-C/low LDL-P, b p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-C/low 
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). All models were adjusted for age, race,  baseline body mass index and   
baseline trait (i.e. delta GlycA adjusted for baseline GlycA). 
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Table 5.16. Delta cardiovascular disease outcomes for LDL discordant/concordant women in the HERITAGE Family Study 
 
  
Low LDL-C/ 
Low LDL-P  
N=160 
(40.7%) 
Low LDL-C/ 
High LDL-P  
N=35 
(8.9%) 
High LDL-C/ 
Low LDL-P 
N=36 
(9.1%) 
High LDL-C/ 
High LDL-P 
N=162 
(41.2%) 
p 
value 
Anthropometrics           
BMI (kg/m2) -0.02 (0.08) -0.02 (0.15) -0.19 (0.15) -0.15 (0.08) 0.5982 
Body Fat (%) -0.73 (0.18) -1.04 (0.37) -0.53 (0.36) -0.68 (0.18) 0.7893 
Visceral abdominal  Fat (cm2) -3.72 (1.1) -4.27 (2.15) -8.61 (2.17) -2.48 (1.09) 0.0963 
Cardiorespiratory Fitness (ml/kg/min)         
VO2max  5.13 (0.23) 5.37 (0.45) 5.34 (0.45) 4.78 (0.23) 0.4857 
Blood Pressure (mmHg)           
Systolic blood pressure 0.59 (0.56) 1.28 (1.13) -0.56 (1.16) -0.79 (0.57) 0.2198 
Diastolic blood pressure 0.98 (0.45) 0.08 (0.9) 0.36 (0.93) 0.09 (0.45) 0.5553 
Carbohydrate/Lipid Metabolism           
Glucose (mmol/L) 0.1 (0.04) 0.16 (0.07) -0.02 (0.08) 0.11 (0.04) 0.348 
Fasting insulin (pmol/L) -7.42 (2.1) -7.62 (4.24) -13.35 (4.34) -5.98 (2.1) 0.5048 
Insulin Sensitivity (μU/min/mL) -0.16 (0.19) 0.44 (0.38) 0.01 (0.39) 0.18 (0.2) 0.4512 
Hepatic Lipase (nmol/mL/min) -3.3 (3.3) -13.11 (6.68) -12.62 (6.58) -12.26 (3.46) 0.2306 
Lipoprotein Lipase (nmol/mL/min) 5.94 (2.16) 2.70 (4.4) 11.06 (4.34) 6.22 (2.23) 0.6021 
Inflammatory Markers           
GlycA (µmol/L) -3.74 (3.13) -7.05 (6.27) -0.48 (6.23) -1.54 (3.19) 0.8409 
C-Reactive Protein (mg/dL) -0.04 (0.04) -0.09 (0.07) -0.05 (0.08) 0.04 (0.04) 0.3016 
a p<0.05 between low LDL-C/low LDL-P, b p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-C/low 
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). All models were adjusted for age, race,  baseline body mass index and   
baseline trait (i.e. delta GlycA adjusted for baseline GlycA).
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Table 5.17. Baseline Lipoprotein subclass outcomes for HDL discordant/concordant groups in the HART-D study 
 
  
Low HDL-C/ 
Low HDL-P  
N=80 (37.56%) 
Low HDL-C/ 
High HDL-P  
N=26 (12.21%) 
High HDL-C/ 
Low HDL-P 
N=28 (13.15%) 
High HDL-C/ 
High HDL-P 
N=79 (37.08%) 
p 
value 
Demographics            
% Male 51.25 53.57 15.38 22.78 <.0001 
% White 63.75 67.86 38.46 46.84 0.0251 
Continuous HDL Discordance (Percentile difference between HDL-C and HDL-P)     
Continuous HDL 
Discordance 
1.81 (4.80)b,c -35.77 (5.67)* 36.77 (5.73)* -2.12 (5.07)b,c <.0001 
L pid P el,  (mg/dL)           
Total Cholesterol 150.74 (9.35)c,d 152.39 (11.05)c 184.27 (11.18)a,b 164.1 (9.88)a <.0001 
Triglycerides 130.53 (19.24)d 141.98 (22.71)d 110.36 (22.98) 93.13 (20.31)a,b 0.0011 
HDL-C  37.47 (2.00)c,d 40.18 (2.36)c,d 51.01 (2.39)* 55.71 (2.11)* <.0001 
LDL-C 87.21 (8.17)c 85.45 (9.66)c 112.83 (9.84)* 90.39 (8.63)c 0.0008 
Lipoprotein Particle Size 
(nm) 
          
HDL-P size  8.71 (0.07)* 8.61 (0.08)* 8.96 (0.08)a,b  8.87 (0.07)a,b <.0001 
LDL-P size 20.54 (0.12)c,d 20.44 (0.14)c,d 21.14 (0.14)* 20.84 (0.12)* <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)     
Total HDL-P  18.86 (0.52)* 22.65 (0.62)* 19.72 (0.63)* 24.03 (0.55)* <.0001 
Small HDL-P  13.36 (0.77)* 17.69 (0.91)* 12.03 (0.92)* 16.02 (0.81)* <.0001 
Medium HDL-P 4.58 (0.56)c,d 3.96 (0.67)c,d 6.23 (0.67)a,b 6.23 (0.60)a,b <.0001 
Large HDL-P 0.92 (0.22)c,d 1.00 (0.26)c,d 1.46 (0.26)a,b 1.78 (0.23)a,b <.0001 
Total LDL-P 1018.28 (79.63) 1011.75 (94.01) 1093.38 (95.12) 1022.65 (84.07) 0.6322 
Small LDL-P 769.06 (79.86)c,d 830.56 (94.29)c,d 562.53 (95.40)a,b 662.73 (84.32)a,b 0.0007 
Medium LDL-P 107.63 (27.75)c 81.66 (32.76)c,d 177.50 (33.15)* 124.47 (29.3)b,c 0.0023 
Large LDL-P 141.8 (41.85)c,d 99.72 (49.41)c,d 353.52 (49.99)* 235.49 (44.19)* <.0001 
a p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low HDL-
P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). Demographics were assessed via chi-square. All models other were adjusted for age, 
race, sex, and baseline body mass index.
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Table 5.18. Baseline cardiovascular disease risk factor outcomes for HDL discordant/concordant groups in the HART-D study 
 
  
Low HDL-C/ 
Low HDL-P  
N=80 (37.56%) 
Low HDL-C/ 
High HDL-P  
N=26 (12.21%) 
High HDL-C/ 
Low HDL-P 
N=28 (13.15%) 
High HDL-C/ 
High HDL-P 
N=79 (37.08%) 
p 
value 
Anthropometrics (not adjusted for baseline BMI)         
BMI (kg/m2) 33.58 (1.61) 35.05 (1.90) 34.01 (1.93) 32.4 (1.70) 0.1445 
Waist Circumference (cm) 109.44 (3.71) 113.86 (4.39) 110.83 (4.44) 106.43 (3.91) 0.0512 
Body Fat (%) 36.91 (1.38) 37.06 (1.65) 38.36 (1.66) 35.90 (1.45) 0.1197 
Cardiorespiratory Fitness (ml/kg/min)         
VO2max  18.50 (0.81) 18.85 (1.02) 18.28 (1.10) 18.92 (0.90) 0.8007 
Blood Pressure (mmHg)           
Systolic blood pressure 131.45 (4.02) 132.42 (4.75) 128.26 (4.81) 131.96 (4.25) 0.6433 
Diastolic blood pressure 71.58 (2.38) 71.49 (2.82) 71.10 (2.85) 72.70 (2.52) 0.754 
Carbohydrate/Lipid Metabolism         
Glucose (mg/dL) 142.15 (10.16) 136.26 (11.99) 133.47 (12.14) 139.77 (10.73) 0.6844 
Insulin (pmol/L) 38.33 (3.77)c,d 34.10 (4.46) 30.10 (4.51)a 32.26 (3.98)a 0.0095 
Hemoglobin A1C (%) 8.10 (0.33) 7.79 (0.39) 7.60 (0.39) 7.87 (0.35) 0.204 
Inflammatory Markers           
GlycA (µmol/L) 425.23 (17) 442.00 (20.08) 413.92 (20.31) 420.57 (17.95) 0.3107 
C-Reactive Protein (mg/L) 5.62 (1.80) 4.15 (2.13) 2.85 (2.15) 4.92 (1.90) 0.232 
a p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low HDL-P, d p<0.05 
between high HDL-C/high HDL-P, * p<0.05 between all other groups 
Values are presented as mean (standard error). Demographics were assessed via chi-square. Unless otherwise noted, all models were 
adjusted for age, race, sex, and baseline body mass index.
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Table 5.19. Baseline Lipoprotein subclass outcomes for LDL discordant/concordant groups in the HART-D study 
 
  
Low LDL-C/ 
Low LDL-P  
N=81 (38.38%) 
Low LDL-C/ 
High LDL-P  
N=24 (11.37%) 
High LDL-C/ 
Low LDL-P 
N=22 (10.43%) 
High LDL-C/ 
High LDL-P 
N=84 (39.81%) 
p 
value 
Demographics            
% Male 38.27 27.27 37.50 35.71 0.817 
% White 45.68 81.82 37.50 60.71 0.0041 
Continuous LDL Discordance (Percentile difference between LDL-C and LDL-P)     
Continuous LDL 
Discordance 
-0.05 (3.94)b,c -34.44 (4.73)* 28.89 (4.61)* -0.06 (3.94)b,c <.0001 
L pid P el,  (mg/dL)           
Total Cholesterol 129.56 (6.90)* 144.41 (8.29)* 166.26 (8.08)* 182.66 (6.90)* <.0001 
Triglycerides 113.74 (18.72)b 146.08 (22.47)a,c 86.62 (21.90)b,d 127.14 (18.72)c 0.0082 
HDL-C  42.24 (3.06)c 42.46 (3.67)c 50.70 (3.58)* 42.72 (3.06)c 0.0033 
LDL-C 65.03 (5.31)c,d 72.68 (6.37)c,d 100.33 (6.21)* 114.61 (5.31)* <.0001 
Lipoprotein Particle Size 
(nm) 
          
HDL-P size  8.74 (0.07) 8.74 (0.09) 8.89 (0.09) 8.76 (0.07) 0.0539 
LDL-P size 20.54 (0.13)c,d 20.41 (0.15)c,d 20.97 (0.15)* 20.74 (0.13)* <.0001 
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L) 
  
  
  
Total HDL-P  20.89 (0.87) 21.20 (1.05) 20.60 (1.02) 19.88 (0.87) 0.0882 
Small HDL-P  14.44 (0.96) 14.90 (1.15) 13.23 (1.12) 14.05 (0.96) 0.2741 
Medium HDL-P 5.32 (0.62) 5.06 (0.75) 5.84 (0.73) 4.69 (0.62) 0.0708 
Large HDL-P 1.13 (0.25) 1.26 (0.30) 1.54 (0.29) 1.16 (0.25) 0.1706 
LDL-P 796.01 (52.34)* 1094.06 (62.82)* 922.80 (61.24)* 1259.20 (52.33)* <.0001 
Total Small LDL-P 604.41 (71.91)b,d 867.63 (86.31)a,c 527.33 (84.15)b,d 874.57 (71.90)a,c <.0001 
Medium LDL-P 82.69 (28.15)c,d 112.70 (33.80) 125.82 (32.95)a 146.10 (28.15)a 0.0004 
Large LDL-P 109.02 (43.50)c,d 113.74 (52.21)c,d 269.86 (50.90)a,b 238.76 (43.50)a,b <.0001 
a P<0.05 between low LDL-C/low LDL-P, b P<0.05 between low LDL-C/high LDL-P, c P<0.05 between high LDL-C/low LDL-
P, d P<0.05 between high LDL-C/high LDL-P, * P<0.05 between all other groups 
Values are presented as mean (standard error). Demographics were assessed via chi-square. All other models were adjusted for age, 
race, sex, and baseline body mass index.
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Table 5.20. Baseline cardiovascular disease risk factor outcomes for LDL discordant/concordant groups in the HART-D study 
 
  
Low LDL-C/ 
Low LDL-P  
N=81 (38.38%) 
Low LDL-C/ 
High LDL-P  
N=24 (11.37%) 
High LDL-C/ 
Low LDL-P 
N=22 (10.43%) 
High LDL-C/ 
High LDL-P 
N=84 (39.81%) 
p 
value 
Anthropometrics (not adjusted for baseline BMI)         
BMI (kg/m2) 33.30 (1.66) 34.76 (2.00) 32.89 (1.94) 33.35 (1.66) 0.6806 
Waist Circumference (cm) 108.25 (3.84) 112.34 (4.61) 107.79 (4.49) 109.51 (3.84) 0.5739 
Body Fat (%) 36.38 (1.41) 37.06 (1.69) 37.54 (1.66) 36.89 (1.41) 0.7224 
Cardiorespiratory Fitness (ml/kg/min)         
VO2max  18.13 (0.81) 19.22 (1.17) 19.57 (1.07) 18.95 (0.81) 0.2048 
Blood Pressure (mmHg)           
Systolic blood pressure 130.65 (4.03) 133.17 (4.83) 131.27 (4.71) 131.70 (4.03) 0.8849 
Diastolic blood pressure 71.32 (2.43) 71.15 (2.92) 72.73 (2.84) 72.16 (2.43) 0.82 
Carbohydrate/Lipid Metabolism         
Glucose (mg/dL) 137.04 (10.32) 139.79 (12.39) 136.48 (12.08) 144.53 (10.32) 0.5209 
Insulin (pmol/L) 34.03 (3.84) 38.36 (4.61) 34.99 (4.49) 37.65 (3.84) 0.2645 
Hemoglobin A1C (%) 7.83 (0.33) 7.89 (0.40) 7.74 (0.39) 8.18 (0.33) 0.1333 
Inflammatory Markers           
GlycA (µmol/L) 421.80 (17.27) 443.11 (20.73) 402.46 (20.21) 428.50 (17.27) 0.1076 
C-Reactive Protein (mg/L) 4.49 (1.85) 6.09 (2.22) 4.75 (2.16) 5.81 (1.85) 0.5012 
a P<0.05 between low LDL-C/low LDL-P, b P<0.05 between low LDL-C/high LDL-P, c P<0.05 between high LDL-C/low LDL-P, d P<0.05 
between high LDL-C/high LDL-P, * P<0.05 between all other groups 
Values are presented as mean (standard error). Unless otherwise noted, all models were adjusted for age, race, sex, and baseline body 
mass index.
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Table 5.21.  Significant parameter estimates for the effect of continuous 
HDL discordance on exercise induced changes in CVD risk factors 
Continuous HDL Discordance Analysis 
  
Parameter  
Estimate P-value 
Continuous HDL Discordance  
(% difference between HDL-C and HDL-P) 
Continuous HDL Discordance  -0.273 <.0001 
Cholesterol Measurements, (mg/dL)   
Triglycerides -0.515 0.0102 
Lipoprotein Particle Size (nm)     
HDL-P size 0.003 0.0003 
Lipoprotein particle concentrations (HDL: µmol/L) 
HDL-P 0.016 0.0162 
Large HDL-P 0.007 0.0002 
Small LDL-P -2.163 0.0025 
All models adjusted for age, sex, race, cholesterol medication,  
baseline BMI and baseline trait (i.e. adjusting for baseline HDL-P 
when assessing change in HDL-P). 
 
Table 5.22.  Significant parameter estimates for the effect of  
continuous LDL discordance on exercise induced changes  
in CVD risk factors 
Continuous LDL Discordance Analysis 
  
Parameter  P-
value Estimate 
Continuous LDL Discordance  
(% difference between LDL-C and LDL-P) 
Continuous LDL Discordance  -0.4949 <.0001 
Cholesterol Measurements, (mg/dL)   
LDL-C -0.2655 0.0097 
Anthropometrics     
Body Fat (%) -0.014 0.0311 
All models adjusted for age, sex, race, cholesterol  
medication, baseline BMI and baseline trait (i.e. adjusting  
for baseline body fat when assessing change in body fat). 
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CHAPTER 6 
OVERALL DISCUSSION 
Purpose 
The purposes of this dissertation were to: 1) examine the cross-sectional 
associations of LDL and HDL discordance with CVD risk factors, 2) investigate the 
association of lipoprotein discordance with risk of incident MetS and T2D, and 3) assess 
the relationship between baseline discordance status and exercise training induced changes 
in CVD risk factors.  
Methods 
The first study examined the cross-sectional associations of lipoprotein discordance 
with CVD risk factor profiles, as well as the relationship between lipoprotein discordance 
and risk of T2D or MetS. Participants from the CARDIA study cohort (N=3891). Subjects 
participated in six exams from year seven to year thirty of the study. Multiple CVD risk 
factors, including a blood lipid panel, were measured at the Year 7 exam with blood 
samples additionally being assessed by NMR spectroscopy for lipoprotein subclass 
profiles. Each individual’s sex specific discordance status was assessed via both median 
based and continuous based discordance as previously described. 
The second study examined the association between lipoprotein discordance and 
exercise training induced changes in multiple CVD risk factors including continuous 
lipoprotein discordance. Two previously completed exercise interventions were used for 
this analysis: HERITAGE (N=715) and HART-D (N=214). In HERITAGE, relatively 
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healthy adults completed a 20-week progressive exercise intervention using cycle 
ergometer exercise, while HART-D included diabetic adults who completed one of four 
nine-month interventions: 1) Control, 2) Aerobic Training, 3) Resistance Training or 4) 
Aerobic and Resistance Training. Baseline and post intervention measurement of multiple 
CVD risk factors were assessed via standardized procedures. Blood samples were taken in 
the morning after a 10 (HART-D) or 12 (HERITAGE) hour fast. Samples for HERITAGE 
were taken twice at baseline and 24 and 72 hours after the last exercise training session. 
Samples for the HART-D study were collected within 48 to 96 hours of the final exercise 
bout. Blood samples were assessed for blood lipid panels and NMR lipoproprofile among 
other risk factors. Similar to the first study, sex specific discordance status was assessed 
via median and continuous based lipoprotein discordance.  
Main Findings  
Among all studies, more favorable CVD risk factor profiles were found in groups 
with higher HDL-C or lower LDL-P regardless of discordance status. High HDL-C groups, 
across all studies, displayed higher mean LDL-P size and large HDL-P concentrations. 
Lower small LDL-P concentrations were found across all High HDL-C groups except for 
females in CARDIA. In HERITAGE and CARDIA, High HDL-C groups displayed lower 
BMI, while in HART-D and CARDIA higher mean HDL-P size was seen in these groups. 
Within the Low LDL-P groups, lower small LDL-P concentrations were seen across all 
studies. In CARDIA and HERITAGE, Low LDL-P groups additionally displayed lower 
triglycerides and BMI along with increased mean HDL-P size (except in males in 
HERITAGE). Thus, having High HDL-C or Low LDL-P is relatively consistently 
 
99 
associated with beneficial lipoprotein subclass profiles. Furthermore, outside of HART-D 
these phenotypes were associated with lower BMI, regardless of discordance.  
In women only in CARDIA, lipoprotein discordance status was associated with risk 
of T2D and MetS over 23 years. Higher risk of both outcomes was associated with lower 
HDL-C and higher LDL-P concentrations. For example, continuous HDL discordance was 
negatively associated with T2D risk, while the Low LDL-C/High LDL-P group was at the 
highest risk of MetS among all median based groups. In most models, only lipoprotein 
discordance and time varying age were found to be significant predictors of T2D or MetS.  
Regarding exercise training induced CVD risk factor changes, lipoprotein 
discordance status was found to be primarily predictive of lipoprotein subclass metrics. 
HDL discordance was primarily predictive of HDL subclass changes, while LDL 
discordance was primarily predictive of LDL subclass changes. Nevertheless, beneficial 
within group changes were seen in both exercise training studies for cardiorespiratory 
fitness, body fat percentage, and medium LDL-P concentrations, independent of 
discordance status.  
Conclusions 
The studies included in this dissertation are the first to examine lipoprotein 
discordance associated risk of either T2D or MetS, as well as the association between 
lipoprotein discordance and exercise training induced changes in CVD risk factors. 
Consistent favorable risk factor profiles were found in groups with High HDL-C or Low 
LDL-P. In women, lipoprotein discordance was a significant risk factor for T2D as well as 
MetS. The results of our study highlight the importance of measuring lipoprotein particle 
concentrations alongside of their respective cholesterol levels in the prevention and 
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management of chronic disease. Although baseline lipoprotein discordance status predicted 
differential lipoprotein subclass changes with exercise training, individuals experienced 
some level of beneficial change in other CVD risk factors in response to exercise training. 
Thus, while lipoprotein discordance may be associated with differential CVD risk factor 
profiles, including T2D and MetS, regular exercise remains an advisable lifestyle factor for 
the improvement and/or maintenance of risk factors associated with CVD and other chronic 
condition
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